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Inherited retinal dystrophies (IRDs) are a large group of genetic diseases that lead to retinal 
degeneration and represent a major cause of vision impairment or blindness. The high genetic 
heterogeneity of IRDs hinders a broad application of gene-specific therapies. There is an unmet 
need for therapies that can target common pathological mechanisms, regardless of the genetic 
cause. MicroRNAs (miRNAs) are important players in retinal biology and my group has 
demonstrated that miR-204 has a pathogenic role in human IRDs. Due to their pleiotropic 
actions, miRNAs represent promising therapeutic tools.  
On this basis, I hypothesized that the modulation of miR-204 levels, as well as other miRNAs, 
could represent a valid approach to tackle retinal degeneration. 
The first part of my thesis elucidates the potential of miR-204 administration as a therapeutic 
approach for IRDs. I found that administration of miR-204 by an adeno-associated viral (AAV) 
vector at patient-relevant stages of disease progression led to a long-term preservation of 
retinal function in a mouse model for a dominant form of Retinitis Pigmentosa (RP). 
Interestingly, transcriptome analysis revealed that miR-204 effect is mediated by dampening 
pathological processes shared by different IRDs (e.g. innate immune response). 
The second part of my work was focused on identifying additional miRNAs that can exert a 
protective action in IRDs in a gene-independent manner. Using a High Content Screening (HCS) 
approach I tested 560 miRNAs in a model of oxidative stress-induced retinal degeneration, the 
light-damage in cone-like cells (661W). As a result, I found that miR-429 significantly preserved 
661W viability during photo-stress. Further analysis revealed that miR-429 overexpression 
increases the activated form of the pro-survival AMP-activated protein kinase (AMPK), recently 
demonstrated to be protective during retinal degeneration. 
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Overall, the results of this thesis indicate that modulation of miRNAs can be a promising 





















1.1 The retina 
The retina is a highly specialized sensory tissue that covers the inner surface of the posterior 
part of the eye. The function of the retina is to capture light stimuli and process them into 
neural information sent to the higher visual centers. The retina is considered part of the central 
nervous system (CNS) considering its neuroectodermal origin. In particular, during 
embryogenesis, the anterior part of the brain produces a bilateral protrusion, the primary optic 
vesicles, that invaginate and give rise to a double-walled formation called the optic cup (1, 2). 
The optic cup comprises the layers that will subsequently become the two main components 
of the retina: the neural retina (NR), which constitutes the sensory part and derives from the 
inner layer of the optic cup, and the retinal pigment epithelium (RPE), originating from the 
outer layer of the optic cup (2) and consisting of a single layer of melanin-containing cells 
 
 
Figure 1. Overview of human eye development during embryogenesis. 
The optic vesicles derive from the forebrain neuroectoderm and induce the adjacent ectoderm to form the lens 
placode (A). The optic vesicle folds in on itself, forming the optic cup, which partially encapsulates the invaginating 
lens vesicle (interrupted posteriorly by the optic fissure) (B). The optic cup subsequently differentiates into two 
main layers, the neuroretina and the retinal pigment epithelium, while the lens vesicle thickens and forms the 
A B C D E 
15 
 
lens (C,D,E). The neural cells in the neuroretina differentiate from the center to the periphery of the optic disc, 
leading to the adult retina pattern, which is formed by circumferential zones enriched in specific photoreceptors. 
Image and caption adapted from Gaspar et al.,2018 (2). 
 
 
The sensory neural retina is responsible for the transformation of photons into electric 
impulses, a process known as phototransduction. These electric signals are then relayed via 
the optic nerve to the visual centers of the brain, where they are further integrated and 
processed to enable visual perception. Such a specialized function requires a highly organized 
architecture shaped in different laminae. Specifically, the structure of the neural retinal is 
composed of six major classes of neurons whose cell bodies are organized in three different 
nuclear layers, the outer nuclear layer (ONL), the inner nuclear layer (INL) and the ganglion cell 
layer (GCL) that alternate with two layers of synaptic neuropils, the inner and outer plexiform 
layer (IPL and OPL) (Figure 2).  
The ONL contains the cell bodies of the sensory neurons, the photoreceptors (PRs), which 
transfer the signal to second order neurons, the bipolar cells, whose cell bodies are located in 
the INL together with the amacrine and horizontal cells. The bipolar cells also communicate 
with third order neurons, the retinal ganglion cells (RGCs), which reside in the ganglion cell 
layer (GCL) and are responsible for the transmission of the electric signal outside the retina via 
the optic nerve. 
In the outer plexiform layer (OPL), the axons of photoreceptors make synapses with the 
dendritic processes of the vertically running bipolar cells and the neurites of the horizontal 
cells, while in the inner plexiform layer (IPL), the bipolar cells connect with the ganglion cells 
and amacrine cells. The horizontal and amacrine cells are important to integrate and modulate 





Figure 2. Organization of the vertebrate retina.  
Histological image overlaid with a schematic diagram of the mature murine retina structure, as an example of the 
vertebrate retina. The photoreceptor cell bodies reside in the outer nuclear layer (ONL) and their outer segments 
(OS) are in contact with the retinal pigment epithelium (RPE). The inner nuclear layer (INL) contains the cell bodies 
of horizontal, bipolar, and amacrine cells, as well as Müller glia. The ganglion cell layer (GCL) contains the cell 
bodies of both ganglion and displaced amacrine cells. Connections between the photoreceptor, bipolar, and 
horizontal cells are found in the outer plexiform layer (OPL), whereas synapses between bipolar, ganglion, and 
amacrine cells occur in the inner plexiform layer (IPL). The ganglion cell (GC) axons form the nerve fiber (NF) layer. 
Image and caption from Bassett and Wallace, 2012 (3). 
 
 
In addition to the aforementioned six classes of neurons, the non-neuronal glial cells 
contribute to the maintenance and functioning of the neural retina. In 1892, Cajal identified 
three main populations of glial cells in the retina that are now classified as Müller cells, 
astrocytes and microglia (4). The retinal glial cell types differ both in terms of distribution and 
function. Müller cells and astrocytes are macroglia cell types. Their processes and end-feet 
encircle the blood vessel, playing a fundamental role in the formation and maintenance of the 
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blood-retina barrier (5). While astrocytes are mostly confined to the innermost layers, Müller 
cells stretch across all the retinal layers (Figure 3). Microglia cells instead are present within 
the different inner layers, including OPL, INL, IPL, GCL and the nerve fiber layer (NFL), but their 
spatial distribution changes under pathological conditions as later discussed in the sections 
1.4.1 and 3.5.  
In terms of function, retina glial cells are important for the maintenance of structural 
architecture and homeostasis, the provision of nutrients, the modulation of neuronal 
communication and synaptic connectivity, and the phagocytosis of neuronal debris. 
Furthermore, microglial cells are the resident macrophages within the CNS and represent the 
main immune cells in the retina. However, it was shown that also Müller cells and astrocytes 




Figure 3. Schematic representation of the glial and neuronal cell types in the mammalian retina. 
Müller cells, astrocytes and microglia are the most abundant types of glia in vertebrate retina. Müller cells 
represent 90% of the retinal glia. They are radially oriented cells and span the entire thickness of the retina. 
Astrocytes are almost exclusively confined to the innermost retinal layers and their presence and distribution is 
correlated with the presence and distribution of retina blood vessels. Both Müller cells and astrocytes have the 
ability to ensheath axons, and to form glial boundaries between the retina and the blood vessels. Microglial cells 
have a small ovoid-shaped cell body and multiple ramifications in the GCL of the normal retina, and they are 
organized into a single sheet that is distributed homogeneously. In healthy conditions they are found at variable 




The retinal pigment epithelium (RPE) separates the neural retina from the underlying capillary 
bed (the choriocapillaris), providing structural, metabolic and functional support to the outer 
neural retina (7). The RPE is important not only for maintaining retinal adhesion but also for 
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supporting the function and integrity of PRs. The latter is achieved by: 1) the phagocytosis of 
the PR shed membranes in the outer segment (OS) and the recycling of key elements for the 
visual cycle; 2) the regulation of the nutrient, molecules and ion flow from the blood to the 
outer retina and vice versa (8); and 3) by partaking in the process of light absorption and 
filtering (9).  
 
 
1.2 An overview of Inherited retinal dystrophies (IRDs) 
IRDs are a broad group of heterogeneous genetic diseases characterized by degeneration of 
the retina that ultimately results in loss of vision and blindness. Collectively, IRDs have an 
estimated incidence of 1:2000 and represent the leading cause of vision loss in people of 
working-age in the Western world (10). The most prevalent form of IRD is Retinitis pigmentosa 
(RP), which affects 1 in 3000-4000 people worldwide. Leber Congenital Amaurosis (LCA) is 
considered the most severe form, with an early onset either at birth or in the first years of life 
(11). Overall, IRDs encompass a complex spectrum of diseases with a large clinical and genetic 
heterogeneity. In this respect, causative mutations have been identified in over 200 genes 
(RetNet, https://sph.uth.edu/retnet/home.htm) that are mainly expressed in the RPE or 
photoreceptors cells. These genes encode proteins with diverse functions in the context of the 
retina; some are structural components of retinal cells, others play important roles in relevant 
pathways, such as phototransduction and the retinoid cycle, among others.  Moreover, 
mutations in the same gene can be associated with different clinical manifestations, further 
extending the heterogeneity of IRDs. In some cases, even patients harbouring the same 
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variants in an IRD gene show different clinical manifestations (12, 13), underscoring the 
complexity of diagnosis and patient management.  
IRDs may manifest either as non-syndromic forms, when the disease phenotype affects only 
the retina, or in the context of syndromic conditions with extraretinal manifestations. An 
example of the latter form is Usher syndrome, in which RP is combined with hearing loss and, 
in some cases, vestibular dysfunction. IRDs can also be classified on the basis of the natural 
history of the disease (progressive or stationary) and the mode of inheritance (autosomal 
dominant, AD, autosomal recessive, AR, X-linked or mitochondrial). IRDs are also commonly 
classified according to the retinal cell type that is primarily affected (i.e. rods or cones). On this 
basis, in Rod-Cone Dystrophies (RCD), such as RP, rods degenerate first and cone demise occurs 
as a consequence of that. On the other hand, in Cone-Rod Dystrophies (CRD), the degeneration 
of cone PRs is usually followed by the subsequent death of rods. In Cone Dystrophies (CD) 
instead, the degeneration of cones does not necessarily impact rod function and viability. At 
the very early stages of the disease, it is possible to discriminate between these two groups 
(i.e. RCD or CRD), depending on whether the initial symptoms are impaired night vision 
(indicative of rod dysfunction) or defects in visual acuity and color vision (due to cone 
dysfunction). However, as the degeneration progresses, it becomes difficult to distinguish 
between the primary rod or cone involvement. Finally, the so-called generalised IRDs (e.g. the 
severe LCA) present the simultaneous degeneration of rods and cones in association with a 




1.3 Suitable experimental models to test therapeutic approaches for IRDs 
1.3.1 Murine models of IRDs  
Several animal models, including rodents, dogs and pigs, are available to study the 
degeneration mechanisms and potential therapeutic approaches for IRDs. Among them, the 
mouse models have been the most widely employed, also due to the abundance of naturally 
occurring mutations causing retinal degeneration. Moreover, genetic manipulation (e.g. 
generation of mutants) is more feasible and affordable in mice compared to larger animals.  
In this section, I will introduce some of the most frequently used IRD models and I will mostly 
focus on those employed or mentioned in the thesis, such as the retinal degeneration 1 (rd1) 
and rd10 mice, the Aryl hydrocarbon interacting protein-like 1 (Aipl1) and the RHO-P347S 
mouse models.       
The naturally occurring rd1 mouse model was described by Keeler in 1924 (14) and represents 
the first murine strain in which retinal degeneration was identified. In 1990, it was shown that 
the retinal degeneration in rd1 is caused by a homozygous nonsense (null) mutation in the 
Pde6b gene (Pde6brd1/rd1) encoding the β-subunit of the rod cyclic guanosine monophosphate 
(cGMP) phosphodiesterase (Pde) 6b, essential for the phototransduction cascade (15). ). In rd1 
mice, rod PR cell death begins at post-natal (PN) day 9 and is completed by PN18. After this 
stage, the cones start to degenerate rapidly and by 4 weeks of age only a single layer of cones 
is left in the outer nuclear layer. The rd10 mouse is another IRD model due to mutations in 
Pde6b (Pde6brd10/rd10). This strain is homozygous for a missense mutation in exon 13 and shows 
a slower progression of retinal degeneration compared to rd1. Specifically, in rd10 mice, most 
rods die by PN35 and the majority of cones by PN50 (16, 17). Both rd1 and rd10 mice are 
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commonly used models of autosomal recessive forms of RP, since mutations in the PDE6B gene 
have been reported in patients with AR-RP. 
The Aipl1 homozygous null mouse (Aipl1-/-) is a model with a faster degeneration compared to 
the rd1 and rd10 mice (18). The Aryl hydrocarbon interacting protein-like 1 (Aipl1) gene plays 
a key role in the stabilization of PDE and the survival of photoreceptors. Mutations in the AIPL1 
gene are responsible for LCA in humans, one of the most severe IRD forms with very early 
onset, leading to complete blindness and loss of electrical responses within the first year of 
life. Such severity is recapitulated in Aipl1-/- mice, which at 4 weeks of age exhibit a complete 
degeneration of photoreceptors and absence of ERG responses. In this model, the retina 
develops normally until P12. After this stage, rod and cone PRs quickly degenerate leading to 
a notable reduction of the ONL thickness, which at P21 comprises only a single row of PR nuclei. 
 
A number of transgenic mice have also been generated to study mutations of particular 
interest. In that respect, a representative example are mutations of the proline-347 of the 
Rhodopsin protein, near its carboxyl terminal end. Amino acid substitutions at this position 
tend to cause severe forms of RP (19). This residue is conserved among visual pigments and six 
different missense mutations have been identified in patients with RP. This indicates that 
proline-347 is important for the function of Rhodopsin (20). The transgenic RHO-P347S mouse 
is a model for autosomal dominant RP caused by the substitution of proline-347 by Serine. This 
model carries a copy of the human Rhodopsin allele in which the proline 347 is replaced by a 
serine and represents a useful tool for the study of the early pathogenic events by which this 
mutation leads to photoreceptor cell death (20). The RHO-P347S mice show a slow progression 
of the retinal degeneration without a major perturbation of the phototransduction up to the 
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early stages of degeneration. Indeed, ERG responses, albeit severely impaired, can be detected 
up to 2-3 months of age (20). This aspect makes the RHO-P347S mice a very useful model to 
assess the retinal function even at late stages as a read-out of therapeutic interventions. 
 
1.3.2 In vitro IRD models: the light-induced damage in 661W cells 
The investigation of strategies aimed at protecting cone photoreceptors is particularly relevant 
to advance the therapeutic options for IRD patients. The visual impairment associated with 
cone degeneration has the most severe impact on patients’ life since daylight vision relies on 
cone functionality. Furthermore, also in rod-cone dystrophies, the death of cone 
photoreceptors that occurs secondarily to the loss of rods is the most debilitating consequence 
of the disease. Therefore, therapeutic approaches that tackle the impairment of cones could 
address the needs of a larger population of patients, regardless of the causative mutation, 
which may also be unknown.  
The use of in vitro models of cone damage is particularly useful for the initial identification of 
cytoprotective compounds because it circumvents the complexity of in vivo systems. The study 
of a therapeutic approach for cone degeneration is even harder in murine models. Being 
nocturnal animals, rodents have a lower rod:cone ratio (98:2) compared to humans (95:5), and 
this relative paucity of cones results in rapid cone degenerations in RP models (21). 
Unfortunately, there are very few reliable cellular models of photoreceptors. One of the most 
commonly used is represented by the 661W, which is a cone-like cell line derived from mouse 
retinal tumors (22, 23). These cells show a neuronal-like morphology with spindle-like 
processes, express cone photoreceptor markers (i.e. blue and green cone pigments, 
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transducin, and cone arrestin) and show photoreceptor functions including retinoid processing 
(24). More importantly, these cells are highly susceptible to light-induced stress (25).  
Light is an environmental risk factor for IRDs and may aggravate the disease progression as 
seen in various forms of RP (26). 661W cells exposed to continuous intense light are extensively 
used in vitro to study the cone photoreceptor damage occurring in human retinal 
degenerations. This is because key events underlying the light-induced damage in 661W 
involve pathological mechanisms, such as mitochondrial and oxidative stress among others, 
which are associated with the secondary degeneration of cones in RP (27). Moreover, 
treatments that enhance the antioxidant cellular response reduce the 661W cell death upon 
light exposure (27, 28). Therefore, the light-induced damage in 661W cells represents a very 
useful tool to test therapeutic approaches that aim to protect PRs in IRDs irrespectively of the 
disease causing-mutation, prior to investigating their effect in complex in vivo systems. 
 
1.4 Beyond the heterogeneity: common pathological events in IRDs 
Several lines of evidence revealed that, besides cell-autonomous mechanisms within 
mutation-bearing photoreceptors, non-cell autonomous mechanisms contribute to 
photoreceptor loss in IRDs (29). In particular, the involvement of the immune response 
mediated by microglial hyperactivation was shown to play an important role both in the 
primary death of rods as well as in the secondary cone degeneration that occurs in RP. 
Furthermore, oxidative stress and metabolic impairment represent additional pathological 
changes that take place during rod degeneration and are independent of the causative 
mutation. These processes seem to be particularly relevant for the secondary death of cones 
(30). Therefore, it is tempting to hypothesize that the modulation of such processes may 
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impact on the progression of rods degeneration, ultimately preventing or slowing down cone 
loss regardless of the genetic lesion.              
 
1.4.1 Microglia activation in retinal degeneration 
Microglia are the resident immune cells within the brain and retina that mainly mediate 
inflammation processes. They also maintain the homeostasis of the surrounding neuronal 
tissues by removing cell debris and regulating the secretion of neurotrophic factors. In the 
healthy retina, the microglial cells are located in the inner retina (GCL, IPL, OPL) and constantly 
scan the environment with their highly motile processes. In the presence of harmful stimuli 
(e.g. pathogens or neurodegeneration), microglial cells rapidly switch from a resting status to 
a reactive phagocytic status, in which they acquire an amoeboid morphology and migrate 
towards the insult site to restore the retinal milieu by releasing molecules (such as the Glial 
cell-derived neurotrophic factor, GDNF; the neurotrophin nerve growth factor, NGF; the brain-
derived neurotrophic factor, BDNF) that protect tissues and initiate repair mechanisms (31, 
32). However, the prolonged or excessive activation of microglia, can also induce damage and 
exacerbate neurodegeneration due to the increased flow of pro-inflammatory compounds 
such as nitric oxide (NO), pro-inflammatory cytokines (e.g. Interleukin-1 beta, IL-1β; Tumor 
necrosis factor alpha, TNF-α; Interferon gamma, IFN-γ; Interleukin-6, IL-6) and reactive oxygen 
species (ROS) that can damage neighbouring neurons (33-35). 
Furthermore, activated microglia express several proteins, e.g. Major 
Histocompatibility Complex class II (MHC-II) and CD68, that are used as markers to determine 





Figure 4. Mechanisms of microglia quiescence and activation related to neuronal degeneration. 
Under normal conditions, resting microglia have a ramified morphology and regulate retinal homeostasis. Retinal 
degeneration triggers microglia activation, proliferation, and migration. Activated microglia adopt an amoeboid 
microglia shape and secrete various bioactive molecules, initially active in tissue repair. Prolonged microglia 
activation can lead to excessive responses and consequent retinal damage. 
Abbreviations: IL1:  Interleukin-1 family; TNF: Tumor necrosis factor; ROS: reactive oxygen species; NO: nitric 
oxide. Adapted from Langmann et al., 2007 (36). 
 
Clinical and laboratory reports demonstrated that the sustained chronic inflammatory 
response observed in RP is associated with a concomitant activation of microglia cells (36-41)   
and with an increase of inflammatory cytokines (37, 42) . In the last years, in vivo studies using 
different models of RP underscored the contribution of retinal microglia in the initiation and 
exacerbation of retinal degeneration. In particular, it was shown that microglia activation is an 
early event that can either precede or coincide with photoreceptor degeneration and directly 
contribute to it (33, 41, 43, 44) . Specifically, Zhao et al. demonstrated that in rd10 mice, 
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activated microglia infiltrate the photoreceptor layer at early stages of degeneration, interact 
with and phagocytose healthy rods, and become more activated in the process (41). The same 
study provided evidence of microglial phagocytosis of healthy photoreceptors in additional 
mouse models of RP (e.g. rd1 and rd16 mice that harbor different mutations compared to rd10) 
as well as in human histopathological specimens. In support of a key role of microglia activation 
in the initiation and progression of photoreceptor degeneration in IRDs, different reports show 
that inhibition or ablation of microglial activation in the context of RP, improves the function 
and survival of rod photoreceptors (41, 44, 45). These improvements were also associated with 
a reduced production of proinflammatory molecules such as TNF-α and IL-1b. However, it is 
important to underline that microglia cells are also required to mediate protective effects for 
photoreceptor survival. In this regard, Wang et al. recently reported that the exogenous 
administration of the transforming growth factor beta 1 (TGF-β1) in different murine models 
of RP can be beneficial for cone survival and that such a protective effect is disrupted by 
pharmacologically depleting the 99 % of the microglia (46).   
Furthermore, Arroba et al. showed that ex vivo and in vivo treatment with insulin-like growth 
factors (IGF-1) reduced the death of photoreceptors in rd10 mouse retinas (47). Interestingly, 
the same study also demonstrated that microglia depletion in explants with clodronate- 
containing liposomes diminished the neuroprotective effect of IGF-1 but also moderately 
reduced photoreceptor cell death in rd10 retinas cultured in the absence of IGF-1 (47). 
Taken together, the above-described studies suggest that microglia have a dual role in the 
pathogenesis of RP which can be both neuroprotective and neurotoxic.  
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In light of this evidence, the modulation of microglia activation may represent the basis for the 
development of mutation-independent therapeutic options that could benefit a wide 
spectrum of IRDs patients. Obviously, such approaches should not abolish completely the 
microglia function, but rather modulate it to achieve a fine balance between their beneficial 
neuroprotective effect while inhibiting excessive pro-inflammatory responses (48). 
 
1.4.2 Oxidative stress and IRDs 
Oxidative stress is generated by the imbalance between the production of ROS and their 
detoxification by the physiological anti-oxidant defence mechanisms, resulting in excessive 
cellular ROS levels. Oxidative stress can lead to structural and functional cellular damage due 
to the modification of proteins, lipids and DNA, especially in mitochondria, and to the 
activation of cell-death pathways (49, 50). 
ROS (e.g. superoxide radical anion (O2˙−), hydrogen peroxide (H2O2), hydroxyl radicals (∙OH), 
singlet oxygen (1O2), nitric oxide radical (NO or NO˙) and peroxynitrite (ONOO−)) are highly 
reactive oxidants. Among them, the non-radical H2O2 exhibits a lower reactivity, but can still 
penetrate cell membranes, including the inner and outer membranes of mitochondria. 
Therefore, H2O2 can react with the cellular iron and generate hydroxyl radicals, the most 
reactive form of oxygen (∙OH), via the Fenton reaction: H2O2 + Fe2+ → ∙OH + −OH + Fe3+ (51, 52)  
ROS can be produced upon exposure to environmental stress (e.g. toxins, light) or as by-
products of endogenous physiological processes such as the aerobic metabolism in 
mitochondria and the protein oxidative folding in the endoplasmic reticulum (ER). In particular, 
the electric transport chain (ETC) reactions in mitochondria are one of the main source of 
cellular ROS (53). 
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In addition, ROS can be produced by dedicated enzymes, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases (Nox) and their dual oxidase relatives (Duox), which are localized 
to various cellular membranes (54).  
ROS have a role in several cellular processes including regulation of gene expression, 
modulation of enzyme activities and amplification of immune response (55). Under 
physiological conditions, the cells are able to prevent excessive oxidative stress through 
antioxidant defense mechanisms for ROS scavenging, both non-enzymatic (e.g. ascorbate, 
carotenoids, glutathione, coenzyme Q10) and enzymatic such as the superoxide dismutase 
(SOD) enzymes, the peroxidase enzymes (e.g. glutathione (GSH) peroxidase) and the catalase 
(CAT). In fact, while low levels of ROS can promote cell survival in response to detrimental 
stimuli, their excessive or prolonged production overwhelms the antioxidant capacity of the 
cell, eventually leading to cell death (55, 56).  
An increase of ROS levels has therefore been associated with pathological conditions that are 
accompanied by decreased antioxidant defenses, excessive energy demand, impairment of 
oxidative phosphorylation, higher tissue levels of oxygen, inflammation, and chronic induction 
of the unfolded protein response (UPR) among others (57-60). The retina is highly susceptible 
to oxidative stress. The choroidal blood vessels expose the retina to high levels of oxygen that 
promote the generation of ROS (61). Furthermore, the maintenance of the photoreceptor 
membrane potential and phototransduction processes require a high metabolic rate which 
leads to elevated levels of ROS as a consequence of the high mitochondrial metabolism(29). 
Oxidative stress is a pathogenic event in many retinal neurodegenerative diseases including 
IRDs, light-induced retinal damage and age-related macular degeneration (AMD) (62).  
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Campochiaro et al. reported increased levels of proteins that have been subject to oxidative 
damage in the aqueous humor of patients with RP compared to control patients. The authors 
also found a depletion of GSH, a major component of the antioxidant defense, in the aqueous 
humor of RP patients, leading to a decrease in the ratio of reduced to oxidized glutathione 
(GSH/GSSG), indicative of ongoing oxidative stress and damage in the eye. Along the same 
lines, Martinez-Fernandez de la Camara et al. had previously reported that patients with RP 
present low total antioxidant capacity, including reduced SOD3 activity and protein 
concentration in the aqueous humor (63).  
The involvement of oxidative stress in IRDs was also shown in studies on animal models of RP 
either in the primary death of rods (64) and its propagation (65, 66)  as well as the secondary 
cone cell death (67, 68). Moreover, oxidative stress, in particular through the activity of NADPH 
oxidases, was shown to contribute to the light-induced retinal degeneration in mice (69). 
Finally, oxidative stress contributes significantly also to the non-cell autonomous cone death 
in RP (21). Upon rod photoreceptor death, the consumption of oxygen is drastically reduced. 
As a result, given that the choroidal flux remains stable, higher levels of oxygen permeate the 
outer retina (70, 71). These changes promote an increased production of ROS, leading to 
oxidative damage of the surviving cells (mostly cones) and eventually to cell death. A relation 





Figure 5. Schematic representation of the mechanism by which oxidative damage can contribute to cone cell 
death in Retinitis Pigmentosa. 
The death of rods reduces oxygen consumption resulting in high tissue levels of oxygen in the outer retina. The 
excess oxygen stimulates superoxide radical production by mismatches in the electron transport chain in 
mitochondria and by stimulation of the NADPH oxidase activity in cytoplasm. The high levels of superoxide 
radicals overwhelm the antioxidant defense system and generate more reactive species including peroxynitrite 
which is extremely damaging and difficult to detoxify. This results in progressive oxidative damage in cones that 
contributes to cone cell death and loss of function. Adapted from Campochiaro et al., 2018 (20). 
Abbreviations: O2, oxygen; O2, superoxide radical; H2O, water; NO, nitric oxide; OH_, hydroxyl radical; ROS, 
reactive oxygen species. 
 
 
For all these reasons, therapeutic strategies aimed at reducing oxidative stress, without 
completely abolishing ROS production and signaling, could delay photoreceptor death and, in 
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particular, prolong the survival and/or prevent the demise of cones in different forms of IRD 
regardless of the causative mutation. Promising results in this direction were reported in 
various mouse models upon treatment with exogenous antioxidants (73, 74) or following 
overexpression of endogenous antioxidant enzymes such as the superoxide dismutase and 
catalase (75, 76). 
 
1.5 Therapeutic approaches for IRDs 
The development of treatment options that are suitable for a large number of IRD patients is 
particularly challenging due to the high genetic and clinical heterogeneity of these conditions, 
Moreover, delivering therapeutic molecules to the retina is further complicated by the 
presence of the Blood-Retina Barrier (BRB), an access-limiting barrier that protects the retina 
from the entry of noxious substances circulating into the blood (e.g. toxin and pathogens), and 
that maintains tissue homeostasis  
To date, only one gene-therapy treatment (LUXTURNATM) is commercially available for a 
specific form of LCA associated with biallelic mutations in the RPE-specific 65-kDa protein 
(RPE65) gene (77). Treatments that are effective for broad populations of patients are 
currently missing. 
Different strategies are under development and their design take into account the subtype of 
IRD, the stage of the disease, and the knowledge of disease genetics and underlying molecular 
pathways (Figure 6). Many of these studies are at the preclinical phase or in early clinical 
development. Nevertheless, there is still an urgent need for neuroprotective therapies to 
tackle common pathological mechanisms, regardless of the specific disease-causing mutation. 
The development of such gene-independent approaches has the potential to address the 
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needs of a larger number of patients compared to gene-based therapies. Gene-independent 
strategies are especially relevant when considering that almost in one third of cases, the IRD-
causing mutations remain unknown (78, 79). In particular, protective strategies able to 
preserve cone viability are of outmost importance for patients’ quality of life as daylight vision 
depends on proper cone function. 
 
 
Figure 6. Stages of photoreceptor degeneration and applicable therapies. 
Degeneration is represented in a graph showing the reduction in photoreceptors cells during degeneration. The 
time-windows of different therapeutic options are drawn below. Gene therapy is appropriate for early stages of 
photoreceptor degeneration and neuroprotective strategies can treat ongoing photoreceptor cell degeneration. 
Both these treatments act on endogenous photoreceptors. Cell replacement, optogenetics and retinal prosthesis 
are strategies to treat patients at advanced/late stages of degeneration. Image and caption adapted from Kutluer 
et al., 2020 (80). 
 
 
1.5.1 Gene replacement/augmentation therapy in IRDs 
Gene augmentation is a promising approach for the treatment of IRDs, considering the 
predominantly monogenic nature of these conditions as well as the advances in deciphering 
their genetic basis. In addition, the eye is a particularly favourable target organ for molecular 
therapy. This is because it is an immune-privileged site, thanks to its delimitation by the BRB, 
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therefore the introduction of foreign antigens, e.g. viral vectors, does not elicit severe 
inflammatory and immunologic responses (81). Moreover, the eye combines accessibility for 
surgical interventions with non-invasive, follow-up diagnostic procedures.  
Gene delivery is usually achieved by the subretinal injection of an AAV vector. This viral system 
is preferred for the administration of therapeutic molecules to the retina, since specific 
serotypes were shown to achieve efficient transduction of retinal cells and displayed an 
excellent safety profile. As a result, AAVs are used in several ongoing clinical trials for other 
genes (82). Moreover, some genes exceed in size the cargo capacity of AAV vectors. This is the 
case for example of the USH2A gene whose mutations are among the most common causes of 
Usher syndrome and non-syndromic autosomal recessive retinitis pigmentosa. To overcome 
such a limitation, pre-clinical studies using dual or triple AAV vectors or micro-genes are 
underway (83, 84). 
To date the only commercially available treatment for an IRD is a gene therapy-based approach 
(LUXTURNATM) for recessive forms of RPE65-LCA. It was approved by the FDA at the end of 
2017 and one year later by EMA. This treatment restores RPE65 levels upon delivery of a 
correct gene copy and improves patients' vision for more than four years post-injection (77). 
Although the number of RPE65-LCA patients that can benefit from such treatment is limited 
(considering also that the presence of viable photoreceptors is a prerequisite for its application 
and successful outcome) LUXTURNATM is a proof that gene therapy holds great promise for 
IRDs. in order to extend the window for therapeutic interventions beyond the early stages of 
degeneration and improve its efficacy, it will be important to assess the combination of gene 
therapy with strategies that block or delay photoreceptor cell death. 
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Gene replacement/augmentation strategies are effective in the context of autosomal recessive 
IRDs (arIRDs) in which the mutations give rise to a non-functional gene product (loss-of-
function disease-causing mechanism). On the other hand, IRDs with a dominant mode of 
inheritance (adIRDs) are more frequently associated with gain-of-function mutations, leading 
to the synthesis of a protein product that can be either toxic to the cells or interfere with the 
proper function of the WT gene product (85). Therefore, therapeutic approaches for adIRDs 
differ from those designed for arIRDs. Specifically, the former take advantage of the genome 
editing system to (i) invalidate both alleles, followed by supplementation of the WT gene, (ii) 
specifically invalidate the mutant allele, with or without gene supplementation, or (iii) to 
correct the mutant allele (86). Strategies of genome editing for IRDs are mostly at a pre-clinical 
stage and progress has been made towards limiting unwanted off-target effects. The first 
clinical study of an in vivo genome editing approach for IRDs started recently (in 2019). It is 
based on the CRISPR/Cas9-system (EDIT-101) for the deep intronic variant c.2991+1655A>G 
in CEP290, a mutation associated with LCA type 10  (87).  
 
1.5.2 Pharmacotherapy and neuroprotection  
Besides gene therapy, other promising approaches for the management of the early stages of 
some IRDs are neuroprotective strategies, and pharmacotherapy which is able to modulate 
the affected biochemical pathways. Pharmacotherapy with visual cycle modulators 
(QLT091001) is under clinical evaluation in patients affected by LCA and RP forms caused by 
mutations in genes that encode key enzymes of the visual cycle, i.e. RPE65 and lecithinretinol 
acyltransferase (LRAT). RPE65 and LRAT are responsible for ensuring proper levels of the 
chromophore 11-cis-retinal, fundamental for the formation of rhodopsin and for rod function. 
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In previous clinical studies, QLT091001 (9-cis-retinyl-acetate) improved patients’ visual 
function regardless of the underlying genetic cause by acting as a replacement for the lack of 
11-cis-retinal and restoring the visual cycle (88). Some transient adverse effects have been 
reported (such as moderate to severe headaches and photophobia) (88). 
Photoreceptor cell death in IRDs occurs either as the direct result of the causative mutation or 
due to concomitant, secondary pathological mechanisms such as oxidative stress, metabolic 
impairment, inflammation or loss of protective factors. Therefore, neuroprotective treatments 
that increase pro-survival pathways or interfere with cell death mechanisms or secondary 
detrimental processes could help preserve vision across different forms of IRDs by halting or 
preventing photoreceptor cell death. 
The Rod-derived cone viability factor (RdCVF) is an example of well-studied neuroprotective 
candidates which sustain cell survival mechanisms. It promotes cone survival accelerating 
glucose entry into photoreceptors and stimulating aerobic glycolysis (89). Exogenous 
expression of RdCVF was shown to protect photoreceptors, especially cones, in various pre-
clinical models of IRDs (90), but the study of this molecule has not yet entered the clinical 
phase. The Pigment epithelium derived factor (PEDF) is another promising neuroprotective 
candidate that has shown positive effects on photoreceptor survival in several preclinical 
studies on models of IRDs (91-93). Differently from RdCVF, PEDF exerts its protective effect by 
hindering the increase of intracellular calcium (94) and attenuating the related mechanisms 
that lead to photoreceptor cell death in different forms of IRDs (21, 95, 96). 
Finally, the modulation of processes that are detrimental for photoreceptor cells during retinal 
degeneration (21, 65, 67), such as oxidative stress, was shown to promote cone survival in pre-
clinical studies (73). For example, the antioxidant N-acetyl cysteine (NAC) demonstrated a good 
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safety/efficacy profile also in the initial phase of a clinical evaluation that was recently 
completed (97). 
 
1.5.3 Optogenetic therapy, stem cell transplantation and retinal prosthesis 
Optogenetic therapy, stem cell transplantation and retinal prostheses are the approaches 
under development for the late stages of IRDs when the majority of photoreceptor cells have 
been irreversibly damaged and lost (80).  Optogenetic therapies aim to restore light perception 
by delivering genes encoding light-sensitive proteins in retinal neurons, such as ganglion or 
bipolar cells. Viral vectors are used to deliver the genes encoding for opsins, which are the 
major optogenetic tool (98). Two types of opsin have been described—microbial opsins (type 
I) acting as light-sensitive ions channels or pumps, and animal opsins (type II) which are G 
protein–coupled receptors (99). The type-I opsins (channelrhodopsins, halorhodopsins and 
archaerhodopsins) show a better kinetics compared to the type-II opsins (rhodopsin and 
melanopsin) which present instead a higher light sensitivity. Interestingly, it was recently found 
that the use of a mammalian cone opsin, MW-opsin, provide a combination of speed and 
sensitivity (100). Currently, two clinical studies that uses optogenetic approaches are 
underway but results are not yet available (101).  
Stem cells-based therapies aim at restoring or preserving vision by replacing retinal cells when 
photoreceptors degeneration is already advanced. A potential strategy is based on induced 
pluripotent stem cells (iPSCs). iPSCs are obtained by reprogramming somatic cells at the stage 
of pluripotent cells obtained from patients. The latter could generate both RPE or PR cells to 
reimplant in patients. Gene editing tools should also be applied to correct patient-specific 
mutations. Embryonic pluripotent cells (ESCs) have also been investigated as source of 
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pluripotent cells. ESCs have a high differentiation capacity and would not require gene editing, 
however their use raises ethical concerns. Several protocols have been developed to 
differentiate rod-like cells from iPSCs (102), ECSs (103) and also adult retinal stem cells (104, 
105). However, PRs transplantation strategies are still at the pre-clinical stage and require 
optimization to achieve an efficient integration of engrafted PRs in the host retina.  
On the other hand, clinical testing for RPE cell-therapy is ongoing with promising results (106). 
In any case, further efforts are required for the optimization of protocols in order to obtain 
clinical-grade products and reproducible results.  
Retinal implants can partially restore vision (i.e. identification of large objects, better 
navigation and orientation) in patients with advanced retinal degeneration in which the inner 
retina has retained the ability of signal transmission (86). Four retinal prosthesis have so far 
received market approval in the United States and/or Europe. Briefly, images are captured by 
a video camera and converted by a specialized processor to the stimulation patterns that are 
subsequently delivered to the implanted stimulator chip (87). To date, epiretinal and 
subretinal devices are the most widely documented prostheses. The epiretinal devices are 
implanted on the surface of the neurosensory retina, adjacent to the nerve fiber and ganglion 
cell layers, while subretinal prostheses are placed between the degenerated photoreceptor 
layer and the RPE generating a vision similar to the one that is physiologically generated in the 
eye (86). Argus II, an epiretinal device, is the most widely-used and it has been implanted in 
more than 250 patients to date with encouraging results (88). Finally, for patients with a 
completely degenerated retina the direct stimulation of the cortical cortex by a cortical implant 





microRNAs (miRNAs) are endogenous, small non-coding RNAs with an average length of 22 nt 
that direct the post-transcriptional silencing of target mRNAs. The first example of a miRNA 
was lin-4, described in C. elegans in 1993 (90). Since then miRNAs have been recognized as 
essential regulatory molecules of gene expression, highly conserved across species, and 
potentially involved in all biological processes (107).  
miRNAs originate from DNA sequences that either lie within protein-coding or non-coding 
genes (intragenic miRNAs) or are located in intergenic regions (intergenic miRNAs), possess 
their own promoters and are independently transcribed (108-110). Intragenic miRNAs are 
mostly located within introns even though a few exonic miRNAs have also been reported. 
Intronic miRNAs tend to be transcribed along with their host genes, using their transcriptional 
start sites (TSSs) to initiate transcription (111). However, it has been shown that about 30% of 
intronic miRNA sequences have their own promoters and the transcription is independent 
from their host gene (112). In many cases miRNA-coding regions form clusters, transcribed as 
a single sequence and processed in single miRNAs (113). 
The prevalent mechanism of miRNA biogenesis is termed canonical and involves several 
different steps starting with the transcription of miRNA-coding DNA sequences into primary 
miRNAs (pri-miRNAs) which are then processed into precursor miRNAs (pre-miRNAs) and 
finally into the mature form (Figure 7). The majority of miRNAs are transcribed by RNA 
polymerase II (RNA Pol II) (91). The generated primary miRNAs (pri-miRNAs) contain a 5′ cap 
and a polyA tail (92), like other Pol ll transcripts, and form a stem-loop structure encoding the 
miRNA sequences in the arm of the imperfectly paired double-stranded stem. They are 
processed into pre-miRNAs by the microprocessor complex, which consists of an RNA binding 
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protein, DiGeorge Syndrome Critical Region 8 (DGCR8), and a ribonuclease III (RNAase III) 
enzyme, Drosha (27). DGCR8 recognises various motifs within the pri-miRNA structure (28) and 
guides the positioning of Drosha that cleaves the pri-miRNA duplex about 11 bases from the 
stem base, generating a two nucleotide (nt) overhang at the 3’ end. The result of such 
processing is the so-called precursor miRNA or pre-miRNA, consisting in a hairpin-shaped RNA 
molecule of 70–100 bases.  
The pre-miRNAs are then exported to the cytoplasm by the exportin 5 (XPO5)/RanGTP complex 
where they undergo further processing by the RNase III Dicer. Dicer recognises the 5′ end 
and/or the 2-nt 3′ overhang of the pre-miRNA and cleaves ∼22 nt away from the 5’ end (93, 
94). In humans, Dicer functions together with the dsRBP trans-activation-responsive RNA-
binding protein (TRBP). The Dicer cleavage removes the loop and generates a double stranded 
RNA of 22 bases in length (95). The miRNA duplex contains two forms of miRNAs, one deriving 
from the 5′ end of the pre-miRNA hairpin and named 5p strand and a strand originating from 
the 3′ end named 3p. Finally, in a process termed RNA-induced silencing complex (RISC) 
loading, the double-stranded miRNA produced by Dicer is handed over to a member of the 
Argonaute (AGO) protein family, which selects one strand to become the mature miRNA (also 
known as guide strand) and discards the other strand (passenger strand; also known as 
miRNA*) (96, 97). AGO proteins loaded with miRNAs dissociate from Dicer and form the 
miRNA-induced silencing complex (miRISC) (96). 
For any given miRNA, the proportion of AGO-loaded 5p or 3p strand varies greatly depending 
on the cell type or cellular environment, ranging from near equal proportions to predominantly 
one or the other (98). The selection of the 5p or 3p strand is based in part on the 
thermodynamic stability at the 5′ ends of the miRNA duplex or a 5′ U at nucleotide position 1 
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(99). Generally, the strand with lower 5′ stability or 5′ uracil is preferentially loaded into AGO, 
and is deemed the guide strand (100). 
Upon loading of mature miRNAs onto the miRISC complex, the miRNA guides RISC to 
complementary sequences located mainly in the 3ʹ untranslated region (UTR) of its target 
mRNAs. However, miRNA target sites have also been detected in other mRNA regions including 
the 5′ UTR and coding sequence (114-116). The miRNA sequence between nucleotides 2 and 
7 at the 5’ end contains the so-called seed sequence that is considered particularly important 
for target-recognition (101). Additional nucleotides (particularly nucleotide 8) and paring at 
the 3′ end of miRNAs contribute to the stability and specificity of the miRNA-target interaction 
(116, 117). 
The degree of complementarity between the miRNA and its target leads to the mRNA 
degradation and/or translational suppression (118, 119). In animals, the majority of miRNA-
target interaction contain mismatches. A full complementarity is more likely to induce target 
degradation, through stabilization of the interaction with AGO2. In animals, the majority of 
miRNA-target interactions contain central mismatches that results in inhibition of protein 
synthesis by miRISC either repressing translation or promoting mRNA deadenylation and decay  
(120, 121). Besides the mature miRNA and the AGO protein that directly bind the miRNA, 
glycine-tryptophan protein of 182 kDa (GW182) proteins (in mammals, the trinucleotide 
repeat containing gene 6 (TNRC6) proteins) are key components of the miRISCs, acting as 
downstream effectors in the repression (122). Specifically, they mediate the interaction with 
other effector proteins, such as deadenylase complexes poly(A)-specific ribonuclease 2 
(PARN2)–PARN3 or carbon catabolite repressor 4 (CCR4)–negative regulator of transcription 
(NOT), which shorten the poly(A) tail of the mRNA. Shortening of the mRNA poly(A) tail triggers 
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the removal of the 5’ cap of the mRNA (decapping), allowing for a rapid 5′−3′ degradation by 
exoribonuclease 1 (XRN1) (121). 
The CCR4-NOT complex may 
also induce translational 
repression but the repression 
may also involve the release of 
other factors (123).  
The processes described above 
are illustrated in Figure 7. This 
figure also shows an example of 
an alternative, Drosha-
independent processing of 
miRNAs that occurs for 
mirtrons. The latter are very 
short introns and their 
corresponding pre-miRNA is 
directly released by splicing and 
debranching (118). 
 
Figure 7. miRNA processing. 
MicroRNAs (miRNAs) are processed from RNA polymerase II generated transcripts. In the canonical pathway, 
primary precursor (pri-miRNA) processing occurs in two steps catalysed by Drosha and Dicer that operate in 
complexes with dsRNA-binding proteins (dsRBPs) (i.e. DGCR8 and transactivation-responsive (TAR) RNA-binding 
protein (TRBP) in mammals). The Drosha–DGCR8 complex processes the pri-miRNA into an ~70-nucleotide 
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precursor hairpin (pre-miRNA), which is exported to the cytoplasm. Some pre-miRNAs are produced from very 
short introns (mirtrons) as a result of splicing and debranching, thereby bypassing the Drosha-DGCR8 step. In 
either case, cleavage by Dicer, assisted by TRBP, in the cytoplasm yields an ~20-bp miRNA/miRNA* duplex. In 
mammals, Argonaute 2 (AGO2), which has RNaseH-like endonuclease activity, supports Dicer processing by 
cleaving the 3′ arm of some pre-miRNAs, thus forming an additional processing intermediate called AGO2-cleaved 
precursor miRNA (ac-pre-miRNA). Following processing, one strand of the miRNA/miRNA* duplex (the guide 
strand) is preferentially incorporated into a miRNA-induced silencing complex (miRISC), whereas the other strand 
(passenger or miRNA*) is released and degraded (not shown). Image and caption modified from Krol et al. 2010 
(118) 
 
Although miRNAs influence gene expression mainly by post-transcriptional inhibition, some 
studies also report a miRNA-mediated translational activation that seems to occur under 
specific conditions. This activation was observed in quiescent cells such as oocytes (124), or 
during cell-cycle arrest (125) as well as during amino acid starvation (126), upon binding of 
miRNAs to the 5′ UTR of mRNAs encoding ribosomal proteins. However, the specific conditions 
that elicit this miRNA-mediated activation of translation are not yet fully elucidated. 
A single miRNA can bind multiple mRNA targets (127), possibly modulating entire signaling 
pathways. In that respect, miRNAs act as pleiotropic molecules that fine-tune gene networks 
and stabilize them against aberrant fluctuations due to cellular stress (128, 129). In this 
complex regulatory network, miRNAs can regulate at least 30% of the human genes (107, 130) 
involved in nearly all physiological processes (e.g. developmental timing (131), circadian 
rhythm (132), cell proliferation (133), differentiation (134) and death (135), haematopoiesis 
(136), patterning of the nervous system (137) , etc.). Importantly, aberrant or altered 
expression of miRNAs and their pathways is implicated in the pathogenesis of many human 
conditions (138) including cancer, inflammatory, cardiovascular, neurodegenerative and 
genetic diseases (139).  
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Furthermore, miRNAs have been proposed also as prognostic and diagnostic biomarkers for 
several diseases (140), including retinal degenerations (141). Although miRNAs are mainly 
expressed within the cells, several studies have reported their presence in the extracellular 
space. These extracellular or circulating miRNAs were detected in a wide range of biological 
fluids such as plasma (142) and serum, cerebrospinal fluid (143), saliva, urine (144), and 
vitreous and aqueous humor in the eye (145). Interestingly, their expression seems to follow 
specific patterns in relation to different physio-pathological conditions, thus suggesting that 
circulating miRNAs can be useful biomarkers (146). 
 
1.6.1 miRNAs in the eye  
Over the past years, expression analyses demonstrated that a number of miRNAs are 
significantly expressed in the retina. This suggested that miRNAs have an important role in the 
retina, which is exposed to high environmental stress (147) and, therefore, requires a tight 
regulation of gene expression. 
Notably, my research team generated the first high-resolution expression atlas showing the 
spatiotemporal distribution of miRNAs in the developing and adult WT mouse eye (148). In 
addition to expression analysis based on microarrays, they performed RNA in situ hybridization 
(ISH) experiments for more than 220 miRNAs, and showed their distribution in the retinal 
layers at different developmental stages (148). 
More recently, they also generated the most comprehensive high-resolution analysis of the 
human retina miRNome by Next Generation Sequencing (NGS) procedures that led to the 
identification of novel retina-specific candidate miRNAs as well as to the recognition of a high 
number of sequence variants (isomiRs) (149). 
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Several studies showed that miRNAs have a key role in retinal development and function.  
(147). Some of these studies relied on the disruption of Dicer, the enzyme that is fundamental 
for miRNAs maturation. The constitutive deletion of Dicer in mice leads to early embryonic 
lethality (150). The conditional Knock out (cKO) of key miRNA-processing enzymes allowed 
instead to study the effect of global perturbation of miRNA levels in a tissue-specific manner. 
This approach was used in mice to characterize the influence of miRNA-mediated regulation in 
the mammalian eye (151-153). In this regard, mice that were cKO of Dicer in the developing 
eye displayed an impaired development of the retina, lens, cornea and optic chiasm (152, 154, 
155), indicating a crucial role of miRNAs in the developing eye.  
miRNAs also play a fundamental role in the homeostasis and functioning of the mature retina. 
In particular, the effect of miRNA deficiency on photoreceptor cells has been investigated by 
generating mice with rod- and cone-specific cKO of miRNA-processing enzymes (i.e. Dicer 
and/or Dgcr8). These models were designed in such a way, so that impairment of miRNA 
processing occurred exclusively in mature and differentiated photoreceptor cells (156). 
Disruption of global miRNA levels in the rods of Dicer cKO mice was associated with a 
disorganization of the outer segments followed by retinal degeneration (157). During the pre-
degenerative phase, the mice did not exhibit impairment of the photo-transduction and visual 
cycle, thus suggesting a primary role of miRNA-mediated regulation in rod survival (157). The 
cKO of Dgcr8 in cones resulted in outer segment loss and functional impairment (158). The 
conditional loss of Dicer in cones was associated with a more severe phenotype, characterised 
by enhanced cone death and structural disorganization (159). Collectively, the above-
mentioned studies provided strong evidence of the importance of miRNAs for photoreceptor 
homeostasis, function, and survival (156). 
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Besides the study of global miRNA perturbation, also the modulation of specific miRNAs 
revealed the important contribution of individual or clustered miRNAs in mammalian eye 
development, function and homeostasis. For example, let-7, miR-125, and miR-9 have been 
identified as key regulators of the early to late developmental transition in retinal progenitors 
(160).  
Another miRNA that is highly abundant in the retina and the CNS is miR-124 (161). Deletion of 
the locus encoding miR-124a-1, the paralog that is predominantly expressed in the developing 
retina, severely interfered with the maturation and survival of cones (162).  
The miR-183/96/182 cluster has an important role in multiple sensory tissues and is 
particularly abundant in photoreceptors. Studies based on the inactivation of miR-183/96/182 
in mice suggested that these miRNAs are important for the differentiation and morphogenesis 
of photoreceptors, for the phototransduction pathway, as well as for the regulation of key 
genes of the synaptogenesis and synaptic function (163). Zhu et al. generated a transgenic 
mouse model expressing a miRNA sponge for all three miRNAs of the miR-183/96/182 cluster 
in mature rods (164). The resulting sequestration of miR-183/96/182 did not produce 
detectable morphologic or functional differences compared to the WT. However, the 
disruption of miR-183/96/182 activity sensitized the transgenic mice to retinal damage upon 
light exposure, indicating that this cluster protects rods under stress conditions (164). Along 
the same line, the delivery of miR-182 and miR-183 in Dgcr8 cKO cones, i.e. cones depleted of 
all miRNAs, was reported to prevent loss of cone outer segments (156, 158). 
Finally, miR-204 is another abundant and well-studied retinal miRNA. It is essential for key 




1.6.2 miRNAs and retinal degenerations 
Several studies have reported altered miRNA expression in human and animal models of 
retinal dysfunction, suggesting that miRNAs participate to the pathogenesis of retinal diseases 
including diabetic retinopathy (165), macular degeneration and inherited retinal dystrophies 
(166). In that respect, Loscher et al. reported the down-regulation of miR-96, miR-182, and 
miR-183, and the up-regulation of miR-1, miR-133, and miR-142 as a common pattern in four 
models of RP with different underlying mutations and inheritance patterns (167). Specifically, 
this was shown in two rhodopsin (Rho) mutant mice models (Rho-/- and transgenic RHO-P347S) 
and in two RDS/Peripherin mutants (rds–/– and transgenic RDS–Δ307). This study suggested 
that aberrantly expressed miRNAs are involved in RP regardless of the nature of the causative 
mutation.  
The miRNA expression profile in early retinal degeneration was recently studied in the rd10 
mouse, a commonly used model of autosomal recessive RP (166). The expression profiles of 
1900 miRNAs were analysed by microarray (168). miR-6240, miR-6937-5p, miR-3473b, and 
miR-7035-5p were differentially expressed at P15, a stage that immediately precedes 
photoreceptor death, prompting the authors to suggest that these miRNAs are likely to be 
involved in the onset of the disease (168).  
Furthermore, miR-9, miR-23a, miR-27a, miR-34a, miR-146a and miR-155 have been proposed 
as potential biomarkers for AMD, a multifactorial and progressive retinal degeneration with 
late onset. The dysregulation of their expression was indeed confirmed in the serum of AMD 
patients (141).  
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Although multiple studies reported miRNAs whose aberrant expression is associated with 
retinal degenerations, a direct causative role of a miRNA in the pathogenesis of IRDs in humans 
was shown only for miR-204 (169).  
 
1.6.3 miR-204  
In the human genome, miR-204 is located within intron 8 of the transient receptor potential 
(TRP) channel gene, TRPM3, on chromosome 9q21.12.  
Mir-204 is predominantly expressed in the eye, especially in the RPE, neural retina, lens and 
ciliary body (161, 170) and its expression pattern is evolutionary conserved across fish, mouse 
and humans (149, 161, 169, 171, 172). In particular, within the neuroretina, miR-204 is 
expressed in the retinal ganglion cell layer, inner nuclear layer, and in photoreceptors (169). In 
mammals, miR-204 has a closely related paralog, the miR-211. Their sequences differ by one 
or two nucleotides, depending on the species, but display the same seed sequence thereby 
they most likely target common pathways. 
Over the past years, the Banfi's group has extensively characterized the role of miR-204 in the 
eye. By using the medaka fish (Oryzias latipes) model organism, they showed that the fish 
homolog of miR-204 influences multiple events of eye formation, such as lens differentiation 
and optic cup development (172, 173). Furthermore, they demonstrated that miR-204 is 
necessary for photoreceptor cell function and survival (169). Importantly, they identified a 
point mutation in the seed region of miR-204 and demonstrated that it is responsible for an 
autosomal dominant form of retinal dystrophy in patients, accompanied by eye coloboma, a 
genetic developmental disorder characterized by keyhole-shaped defects in various eye 
structures (169). Furthermore, the authors of the latter study hypothesized that the effects of 
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the mutated miR-204 are mainly mediated by a gain-of-function mechanism consisting in the 
aberrant recognition of novel targets. This study (169) represents the first report of a causative 
relation between a miRNA and a form of IRDs in humans.  
Given its key role in retina development, function and disease, miR-204 emerged as an 






AIM OF THE THESIS 
MiRNAs are fine modulators of gene expression that act as pleiotropic molecules able to 
influence functionally coordinated pathways. This feature makes miRNAs attractive 
therapeutic targets to counteract multiple pathological processes that underlie human 
diseases. Recent evidence supported a role of the miRNA miR-204 in the pathogenesis of IRDs. 
However, it has not yet been explored whether modulating miRNA expression can have a 
protective effect in IRDs.  
IRDs are characterised by high genetic heterogeneity and the availability of therapies for a 
large number of patients is still challenging. The general aim of my thesis project was to 
address this issue by exploring the ability of miRNAs to counteract disease-exacerbating 
processes that accompany IRDs regardless of the specific diseases-causing mutation. I also 
aimed to better understand the role exerted by miRNAs in retinal degeneration, and explore 
their potential as molecular tools in Gene Independent Therapies (GITs) for IRDs. The work 
consists of two main parts: 
 
⮚ Exploring the translational potential of a miR-204-based therapeutic approach 
Encouraging data about a beneficial role of miR-204 in IRDs were generated by Banfi’s 
group. Early (PN4) subretinal delivery of miR-204 in two different preclinical models of 
IRDs yielded a protective effect, suggesting that this miRNA could act in a gene-
independent manner. The models were the transgenic RHO-P347S mice that 
recapitulates an autosomal dominant form of RP, and the Aipl1 -/- mice, model of a 
recessive form of LCA. In the first part of my thesis work, I used the RHO-P347S mouse 
model to investigate whether miR-204 delivery was able to counteract retinal 
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degeneration at advanced postnatal ages which better represent patient-relevant 
disease stages. I also characterized the possible mechanisms underlying its effect. 
 
⮚ Screening of miRNAs able to target pathological process common to different forms of 
IRDs 
In the second part of my thesis work, I sought to identify additional miRNAs able to 
protect PRs against the damage induced by processes that contribute to disease-
progression but are independent of the causative mutation. This is the case, for 
example, of the oxidative stress, which has a key role in the secondary death of cones 
in RP. Cone dysfunction and loss leads to the most debilitating visual impairment and 
occurs in almost all forms of RP, even though the disease-causing mutation may affect 
genes with rod-specific expression. I used the light-induced damage in the 661W cells 
as an in vitro model of PR cell degeneration, particularly cone degeneration, which is 
related to oxidative stress and is independent of specific mutations. The HCS approach 






2 MATERIALS AND METHODS 
 
2.1 Animal Models and Procedures 
For subretinal injections in the RHO-P347S background, pups were obtained by crossing the 
RHO-P347S transgenic (20) with C57BL/6 mice. The C57BL/6 strain was used as a wild-type 
(WT) control line. Studies were conducted in accordance with the institutional guidelines for 
animal research and approved by the Italian Ministry of Health (D.L. 116/92 art. 7; protocol 
number: 650/2018-PR). Mice were maintained under specific pathogen-free (SPF)-like 
conditions at the TIGEM Animal Facility. Surgical procedures were performed under 
anesthesia, and all efforts were made to minimize suffering. Viral vectors were delivered 
subretinally in the dorsal retinal areas via a trans-scleral transchoroidal approach (174). Eyes 
were injected with 1 microliter (µL) of an AAV vector/vector mix (specified in each figure) 
containing a total of 1.1 X 109 viral GCs. 
 
2.2 Electroretinography 
Electrophysiological recordings were performed as previously described (175). Mice were dark 
adapted for 3 hours (h) and accommodated in a stereotaxic apparatus under dim red light. 
Pupils were dilated with a drop of 1% tropicamide (Alcon Laboratories, Fort Worth, TX, USA), 
and the body temperature was maintained at 37.5°C. ERGs were evoked by 10-ms flashes of 
different light intensities ranging from 10-4 to 20 cd·s/m2, generated through a Ganzfeld 
stimulator (CSO, Florence, Italy). To minimize the noise, three different responses evoked by 
light were averaged for each luminance step (the time interval between light stimuli was 4–5 
min). Electrophysiological signals were recorded with gold-plated electrodes inserted under 
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the lower eyelids in contact with the cornea. Electrodes in each eye were referred to a needle 
electrode inserted subcutaneously at the level of the corresponding frontal region. The 
different electrodes were connected to a two-channel amplifier. Amplitudes of a- and b-waves 
were plotted as a function of increasing light intensities. After completion of responses 
obtained in dark-adapted conditions (scotopic), the recording session proceeded to dissect the 
cone pathway mediating the light response (photopic). To this end, ERG responses to light of 
20 cd·s/m2 were recorded in the presence of a continuous background light (set at 50 cd· 
s/m2). For each group, the mean a- and b-wave amplitude was plotted as a function of 
luminance (transfer curve) under scotopic and photopic conditions. 
 
2.3 AAV production 
Recombinant AAV2/8 viruses were produced by the TIGEM Vector Core as reported (176) 
Physical titers (genome copies [GCs] per milliliter [GC/mL]) of each viral preparation were 
determined by TaqMan PCR quantification.  
 
2.4 Plasmid construction  
The AAV.CMV.miR204 and AAV.CMV.miR204MUT plasmids were previously generated in 
Banfi’s laboratory (177). Recombinant AAV vectors containing the murine precursor sequence 
of miR-204 under the cytomegalovirus (CMV) promoter were constructed by a two-step 
cloning protocol. 
Initially, the cassette containing the precursor of miR-204 was amplified from mouse genomic 




CGCGGATCCAACATGGGGTTGTTAATCTG-3’ for miR-204. The obtained amplimers were 
subcloned in the TOPO TA Cloning Vector (Invitrogen) and released following digestion with 
NotI and BamHI. The fragment was then cloned into the NotI–BamHI sites of the pAAV2.1-
CMV-EGFP plasmid (178) and used for the production of AAV2/8 vectors. The control vector 
bearing the precursor of miR-204 with a mutated seed sequence was generated by purine-
pyrimidine changes in both arms of the precursor to maintain the same complementarity and 
hairpin structure as shown in Figure 8. 
 
Figure 8. Scheme of the mutated miR-204 seed sequence contained in the pAAV.CMV.miR204 plasmid used to 
generate the AAV.CMV.miR204MUT. 
Sequence of the miR-204 stem-loop in Mus musculus (blue box). The sequence of the mature miR-204-5p (upper 
strand) and miR-204-3p (lower strand) is in purple. The seed region of miR-204-5p is in a red frame. The sequence 
introduced by site-directed mutagenesis to generate the AAV.CMV.miR204MUT control vector is in green. Karali 
et al., 2020 (177). 
 
This was achieved with two sequential steps of site-directed mutagenesis using primer 
extension. The first reaction introduced the modified seed sequence of the mature miRNA (5’-
GGAAAGGG-3’ instead of 5’-TTCCCTTT-3’ at chr19: 22,750,610–22,750,617) and the second 
introduced a sequence complementary to the newly mutated seed at the 3p arm of the 
precursor hairpin (5’-CCCTTTCA-3’ instead of 5’-AAAGGGAC-3’ at chr19: 22,750,660–
22,750,667) (Figure 8). The internal primer pairs containing the desired mutation and 





The external flanking primers, used in combination with the internal mutagenic primers, were 
the ones described above for the amplification of the miR-204 precursor. 
The vector bearing the precursor miR-204 under the control of a photoreceptor-specific 
promoter (pAAV.RHO.miR204) was generated by exchanging the CMV promoter of 
pAAV.CMV.miR204 with the human RHO promoter sequence (179) Briefly, the sequence 
corresponding to the human RHO promoter was released from the pAAV2.1-RHO-EGFP 
plasmid (178) by restriction with Nhe I and Not I and was cloned in the pAAV.CMV.miR204 
backbone, previously digested with the same enzymes. 
 
For the Luciferase assay the 3’ UTR sequences of Xaf1 and Siglec1 were amplified by PCR from 
mouse genomic DNA using the following sets of oligonucleotides that included tags for the SpeI 
restriction site: Forward 5'-GGACTAGTCCCAGATCCCACTAGCTTC-3' and Reverse 5'-
GGACTAGTATGACGATTGCCCTTCTAAC-3' for Xaf1; Forward 5’-
GGACTAGTCAACTCAGGTGCTGTGAAC-3’ and Reverse 5’-
GGACTAGTCCCTTTCAGCATGGTATGTTTATG-3’. The control vector bearing the mutated 
recognition site for the miR-204 seed sequence was generated by PCR site-directed 
mutagenesis to introduce the CGCATAC sequence instead of AAAGGGA at position 1180-1186 
of Xaf1 3’ UTR, and the GCTATCG and CGCTATC instead of AAGGGAA and AAAGGG, respectively, 
at the positions 567-573 and 671-676 of the Siglec1 3’ UTR. The digested PCR products were 




For the transfection of miR-204 in the BV-2 microglial cell-line, the precursor of miR-204 as well 
as that bearing the mutated seed sequence were cloned in the psiUx expressing vector which is 
particularly effective for the production of small non-coding RNAs (180). The precursor 
sequences were amplified from the AAV.CMV.miR204 and AAV.CMV.miR204MUT plasmids, 
respectively, and cloned in the BglII-XhoI restricted psiUx plasmid. 
 
2.5 RNA Extraction, Library Preparation, Deep Sequencing, and Computational 
Analysis 
Total RNA was extracted from mouse retinas using the miRNeasy kit (QIAGEN, Hilden, 
Germany). RNA-seq library preparation and sequencing were performed as previously 
described (181). The RNA-seq data are deposited in NCBI’s Gene Expression Omnibus (GEO: 
GSE121785). Data analysis was performed as reported (181). The threshold for statistical 
significance was FDR <0.1.  
 
2.6 Gene Ontology Enrichment Analysis (GOEA) 
GOEA (182) was performed on the list of up-regulated and down-regulated genes, separately. 
The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) online tool (v. 6.7) was used by restricting the output to BP (BP_FAT) and 
Cellular Component (CC_FAT) terms, with a significance threshold of FDR <10% and ES >1.5. 
Redundant terms and commonly encountered categories were eliminated. The visualization of 





2.7 Luciferase assay 
To test the direct regulation of target genes by miR-204, the vectors bearing the 3’ UTR of 
selected genes or the mutated form (as described in 2.4) were co-transfected with a synthetic 
miR-204 mimic in HeLa cells. HeLa cells were seeded at a density of 40000 cells/well in a 24-
multi-well plate. The cells were cultured overnight at 37°C and 5% CO2 in DMEM supplemented 
with fetal bovine serum (FBS, 10%), penicillin (100 U/ml) and streptomycin (50 milligram 
[mg]/mL). The next morning the cells were transfected with 370 nanogram (ng) of plasmid DNA 
using the PolyFect transfection reagent (Qiagen) according to the manufacturer’s instructions. 
A Renilla expressing vector was also transfected to allow normalization of the transfection 
efficiency. The transfection was performed in triplicate for each condition. Six hours later, the 
cells were transfected with 50 of negative mimic or miR-204 mimic (Dharmacon) using 
INTERFERIN (Polyplus) according to the manufacturer’s instructions. The luciferase activity was 




Immunostaining for retinal and microglial markers was performed as reported (183). Frozen 
retinal sections were washed once with PBS and then fixed for 10 min in 4% paraformaldehyde 
(PFA). Sections were then permeabilized for 15 min in PBS containing 1% IGEPAL CA-630 (Sigma-
Aldrich, St. Louis, MO, USA. Permeabilization and blocking of sections for anti-Iba1, anti-CD68 
staining were performed for 1 h in 0.3% Triton/4% normal goat serum. Antibodies were then 
incubated overnight at 4°C in 0.1% Triton/2% normal goat serum (for dilutions and providers, 
see below). DAPI (Vectashield; Vector Labs, Peterborough, UK) was used for nuclei 
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counterstaining. Sections were photographed using Zeiss (LSM 710) confocal microscopy (Carl 
Zeiss, Oberkochen, Germany).  
The primary antibodies used were anti-Iba1 (1:300; 019-19741; Fujifilm Wako Pure Chemical, 
Osaka, Japan) and anti-CD68 (1:500; MCA1957T; Bio-Rad, Hercules, CA, USA). 
 
2.9 BV-2 microglial cells and lypopolysaccharide (LPS)-mediated activation 
BV-2 are an immortalised murine microglial cell line. BV-2 cells were maintained in Dulbecco’s 
modified eagle medium (DMEM; Life Technologies) supplemented with 10% heat-inactivated 
FBS (Euroclone), L-glutamine at a final concentration of 2 mM and 1% penicillin/streptomycin. 
An incubator with humidified atmosphere of 5% CO2 at 37°C was used to culture the cells. 
The BV-2 cells were transfected with the vector containing the miR-204 precursor and the 
vector containing the precursor of miR-204 bearing a mutation in the seed sequence. After 
transfection (6 h), the cells were incubated overnight with fresh normal medium. Cells were 
subsequently treated with LPS (100 ng/ml; Lipopolysaccharides from E. coli O111:B4; L4391; 
Sigma-Aldrich) for 24 h.  
 
2.10 Real-Time PCR (qPCR) 
Total RNA was extracted from BV-2 cells using the miRNeasy kit (QIAGEN). cDNAs were then 
generated by the Quantitect kit for the qRT-PCR analysis (QIAGEN) according to 
manufacturer’s instructions. Quantitative PCR were performed using SYBR Green Master Mix 
(Roche) and run in triplicate on a Light Cycler 480 instrument (Roche).  
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The primer sequence used were: TNFα-Forward: 5′-GCCTCTTCTCATTCCTGCTTG-3′; TNFα-
Reverse: 5′-CTGATGAGAGGGAGGCCATT-3’; iNOS-Forward: 5′-CTTTGCCACGGACGAGAC-3′; 
iNOS-Reverse: 5′-TCATTGTACTCTGAGGGCTGA-3′; ATP5B, forward primer 5′-
GGCACAATGCAGGAAAGG-3′, reverse primer 5′-TCAGCAGGCACATAGATAGCC-3′  (184). 
 
 
2.11 661W cells 
661W cells are a transformed murine cone cell line derived from mouse retinal tumors that 
was kindly provided to us by Dr. Muayyad R. Al-Ubaidi (Department of Cell Biology, University 
of Oklahoma, USA) (22). The cells were validated by IF staining for S- and M-opsin proteins 
using respectively anti-Opn1mw (anti-M opsin; 1:200; AB5405; Millipore, Burlington, MA, USA) 
and anti-Opn1sw (anti-S opsin; 1:200; AB5407; Millipore, Burlington, MA, USA). 
661W cells were maintained in high-glucose (4.5 mg/mL) Dulbecco’s modified Eagle's medium 
(DMEM High-glucose; Life Technologies) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Euroclone), L-glutamine at a final concentration of 2 mM, 100 U/ml penicillin and 
100 microgram (µg)/mL streptomycin. Cells were not exposed to direct light during feeding or 
passaging and were cultured in a humidified atmosphere of 5% CO2 at 37°C. For the HCS 
experiments the medium was replaced with serum-free High-glucose DMEM before light 
exposure, to sensitize the cell to light-induced damage, as previously reported (185). For the 
MTT and western-blot experiments the 661W were exposed to light in high-glucose DMEM 




2.12 MTT Cell Viability Assay 
For the pilot and hit confirmation experiments of the HCS, the light-induced damage in 661W 
cells was assessed by using the MTT [3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyltetrazolium 
bromide] assay as indicator of cell viability. In fact, viable cells reduce MTT to form purple 
formazan crystals. Following light exposure, the MTT solution was added to the cells at a final 
concentration of 0.5 mg/mL and the plate was placed in the incubator. After 3.5 h the medium 
was carefully removed, the formazan precipitates were dissolved in dimethyl sulfoxide (DMSO) 
and after 30 min of shaking the absorbance was read at 560 nanometer (nm). 661W that 
underwent light exposure were compared with dark control cells. The cell viability (%) was 
calculated by averaging the ratios of absorbance readings of light exposed cells to the dark 
control cells considered as 100% viable.  
 
2.13 High-Content Screening (HCS) 
 
HCS was used to identify miRNAs able to protect the 661W cells from light-induced damage. 
The strategy and workflow of the HCS is described in the Results section 3.8. The human 
miRIDIAN miRNA Mimic Library (384-well format) was used as a source of miRNA mimics. The 
library contains the 2503 human miRNAs reported in the miRBase sequence database, version 
21.0. The miRNA mimic stock solution (1 micromolar [µM]) was dispensed in the test plate 
(ViewPlate-384 Black with Optically Clear Bottom; PerkinElmer) by using the STAR-let liquid 
handling system (Hamilton, Reno, NV, USA). For the reverse transfection, a mix of Opti-MEM 
reduced serum media (ThermoFisher) and the transfection reagent Interferin (Polyplus) were 
used according to manufacturer's instructions. The 661W cells in DMEM (~650 cells/well) were 
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added subsequently using the E1-ClipTip™ Bluetooth™ Electronic Multichannel Pipettes 
(ThermoFisher). Before placing the plate in the incubator, cells were let to recover under the 
cell culture hood for 5-10 min. After transfection (~60 h), the cells were exposed to white LED 
light (~15000 lux) for 6 h. Following light exposure, Hoechst 33342 was added to the media. 
After 15 min the cells were imaged by using the Opera live imaging system (PerkinElmer). The 
Columbus software was then used for the automated analysis of the images as described in 
the Results section 3.8.2. The experiment was performed in three replicates, carried out on 
different days. 
 
2.14 Detection of cellular ROS 
I used CM-H2DCFDA (ThermoFisher), a chloromethyl derivative of the 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) as an indicator of cellular ROS in 661W. This 
reagent passively diffuses into the cells where it undergoes cleavage by the intracellular 
esterase. Subsequent oxidation generates a green fluorescent compound that is retained 
inside the cell. Briefly, the transfection mix containing the miRNA mimics was spotted at the 
bottom of a 96-well plate for imaging and 661W cells were seeded to allow reverse 
transfection (3000 cells/well). After 48 h, the cells were treated with H2O2 (200 µM in DMEM, 
10% FBS) for 3 h and 15 min. The media was subsequently removed and the cells were washed 
gently with PBS and incubated for 30 min with a medium containing 5 µM CM-H2DCFDA in the 
dark at 37˚C, 5% CO2. After rinsing with PBS, the labelled cells were visualized by fluorescence 
microscopy using the Operetta live imaging system with a 20X objective and a standard GFP 
filter, maintaining a low excitation intensity and a short time of exposure (~10 min for the 
image acquisition of the whole plate). The fluorescence intensity and spatial distribution of the 
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green signal were analysed with the Columbus software and verified by visual inspection. The 
total fluorescence was then calculated by correcting for the background. 
 
2.15 Western Blot  
To obtain whole cell lysates, the 661W were homogenized in cold RIPA lysis buffer 
supplemented with protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitors 
tablets (PhosSTOP, Roche), and then incubated for 20 minutes in ice. After centrifugation (13 
000 rpm) for 10 min at 4° C, the supernatants, containing the total protein extract, were 
collected and used for the experiments. Total protein concentration was determined by using 
the Pierce BCA assay (Thermo Scientific). Each sample contained protein extract corresponding 
to 15 µg of proteins and Loading buffer (SDS, Tris HCL pH6.8, Glycerol, Bromophenol Blu, 
Dithiothreitol-DTT). Proteins were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) which was performed using a 7.5% polyacrylamide gel in Tris-
Glycine running buffer.  
The proteins were then transferred from the gel to hydrophobic polyvinylidene fluoride 
membranes (Immobilon-P PVDF Membrane, Millipore) that were subsequently incubated with 
the primary antibodies overnight at 4 °C or for 2 h at room temperature (for dilutions and 
providers, see below). Proteins of interest were detected with horseradish peroxidase 
conjugated goat anti-mouse or anti-rabbit IgG antibody (1:3,000, GE Healthcare) and visualized 
using Pierce enhanced chemiluminescence (ECL) Western Blotting Substrate (Thermo 
Scientific) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). 
Western blot images were acquired using the ChemiDoc-It imaging system (UVP). 
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Densitometric analyses of the western blot bands were performed using the Image J Software 
(National Institutes of Health, Bethesda, Maryland, USA). 
The primary antibodies used were anti-Phospho-AMPKα (Thr172) (1:1000, #2531, Cell 
Signaling Technology-CST), anti-AMPKα (1:1000, #2532, Cell Signaling Technology-CST) and 












Exploring the translational potential of miR-204 overexpression as a 
therapeutic approach for IRDs. 
Over the past years, the Banfi’s research group has produced significant evidence indicating a 
fundamental role of miR-204 in eye development and function. Notably, they found that a 
mutation within the miR-204 seed sequence is responsible for a familial form of retinal 
degeneration in humans. They then explored the effect of miR-204 overexpression in animal 
models of IRDs at early post-natal stages (i.e. at PN4). To this aim, they cloned the precursor 
sequence of miR-204 under the control of the CMV constitutive promoter in an AAV vector of 
the 2/8 serotype (AAV-miR-204). This serotype transduces efficiently the RPE and PRs upon 
subretinal administration in several species, including mice (178, 186). Following subretinal 
injection of the AAV-miR-204 vector in WT mice, miR-204 was correctly processed and 
expressed, without evident changes in retinal structure and function (177). In addition, the 
subretinal injection of the miR-204 AAV vector in different IRD models (namely, the Aipl1-/- and 
the RHO-P347S mouse lines) at PN4 was associated with a significant reduction of retinal 
degeneration (177). These data suggested that miR-204 could exert a protective effect on IRDs 
in a gene-independent manner.  
With the first part of my thesis work, I contributed to the study of the protective effect of miR-
204 in IRDs. I hypothesized that miR-204 overexpression could slow down the progression of 
retinal degeneration upon administration at later stages. In that respect, the data produced 
on mice at PN4 represented encouraging premises. However, such an early stage (i.e. PN4) 
does not correspond to a time of intervention that can be relevant in humans. Therefore, my 
work focused on exploring the effect of miR-204 overexpression at later postnatal time-points 
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that better represent the patient-relevant disease stages. The retinal degeneration proceeds 
more slowly in the RHO-P347S model compared to Aipl1-/- mice and visual activity can be 
recorded in RHO-P347S up to 3 months after birth. The fast degeneration occurring in the 
retina of Aipl1-/- mice does not allow an effective analysis of interventions at later time-points.  
I therefore used the RHO-P347S mice to further investigate the translational potential of miR-
204 as a therapeutic approach for IRDs because the rate of degeneration in this model allows 
an appropriate window of therapeutic intervention starting from post-developmental stages. 
  
 
3.1 Subretinal injection of pre-miR204 at PN14 preserves visual function in RHO-
P347S mice at PN30 and PN60 
To explore whether miR-204 overexpression could impact IRD progression upon delivery at 
more clinically relevant stages, I assessed the functional effect of the AAV-miR204 
administration at later postnatal timepoints in RHO-P347S mice exploiting the moderate rate 
of retinal degeneration in this model. I first tested the effect of miR-204 overexpression at 
PN14, when the mouse retina is fully differentiated but signs of degeneration are not yet 
evident. These experiments were performed in collaboration with Prof Enrico Maria Surace 
and Elena Marrocco. A group of RHO-P347S mice was treated according to the injection 
scheme shown in Figure 9. Specifically, we injected one eye with 1x109 GC of AAV.CMV.miR204 
and the contralateral one with a control vector mix containing 1x109 GC 
AAV.CMV.miR204MUT, a control vector that drives expression of the miR-204 precursor 
sequence with a mutated seed sequence (177). An EGFP-expressing vector (AAV.CMV.EGFP) 
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was co-injected in either eye at a 1:10 ratio (i.e. 1x108 GC) to assess virus distribution. We then 
recorded retinal function by electroretinogram (ERG) at PN30 (n=18) and PN60 (n=13).  
 
Figure 9. Schematic representation of the experimental design. 
 
The ERG detects the electric signal generated by the retina in response to a light stimulus. 
Specifically, it consists in measuring the amplitude of the a- and b-wave. The a-wave reflects 
the electrical activity deriving from the initial photoreceptor response. The b-wave indicates 
the activity of the downstream bipolar-Müller cell complex, whose light response is initiated 
by synapses with photoreceptors (187), and constitutes the most prominent component of the 
ERG response. The amplitudes of the a- and b-waves are plotted against the light intensities, 
both in dark-adapted scotopic conditions, in which the response is mediated by rods, as well 
as in light conditions which evoke cones response. 
I observed a significant increase of the b-wave amplitude and a trend of preservation of the a-
wave amplitude in the miR-204 treated eyes compared to the control eyes at PN30 (Figure 
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10A). In particular, the difference is evident and statistically significant for the b-wave 
component in response to the highest luminances (i.e. 10 and 20 cd.s/m2) under scotopic 
conditions (Figure 10A, right panel). Under these conditions, the ERG response is related to a 
mixed rod-cone activity. These results indicate that the overall retinal function of RHO-P347S 
mice is significantly preserved upon overexpression of miR-204 by subretinal injection at PN14. 
Noteworthy, the protective effect of AAV-miR-204 injection persisted up to six weeks post-
injection, as shown by the fact that an improved ERG response was still observed at PN60 both 
for the a-wave and b-wave components (Figure 10B). Taken together, these results suggested 
that miR-204 overexpression at early stages of the disease is able to preserve visual function 







Figure 10. Protective effect of miR-204 injection at PN14 in RHO-P347S mice. 
ERG analysis of RHO-P347S mice injected with the AAV.CMV.miR204 and control vector at PN14. Retinal function 
was better preserved in miR-204 treated eyes vs contralateral eyes injected with the control vector at PN30 (A, 
n=18) and PN60 (B, n=13), as indicated by a statistically significant increase in b-wave amplitudes at a light 
stimulus of 10 and 20 cd.s/m2  










3.2 Subretinal injection of pre-miR204 at a stage of advanced degeneration (PN24) 
preserves visual function in RHO-P347S mice  
In order to explore the translational potential of miR-204 overexpression as a therapeutic 
approach for IRDs, I assessed the effect of miR-204 delivery at later postnatal stages that would 
recapitulate more closely those exploitable for clinical applications in human patients. To this 
end, in collaboration with Prof Enrico Maria Surace and Elena Marrocco, we administered the 
AAV-miR204 vector in RHO-P347S mice at PN24, which is a stage of advanced retinal 
degeneration. Subretinal injections were performed using the above-mentioned viral doses 
and injection scheme. We recorded the ERG responses directly at PN60 to allow adequate time 
for the AAV vector to effectively transduce the retinal cells before assessing possible 
outcomes. Consistently with the experiments conducted at earlier timepoints, I observed an 
increased amplitude of the scotopic ERG response at high luminances in mice treated with the 
AAV-miR204 vector compared to those injected with the control. Notably, this difference was 
statistically significant for both a-wave and b-wave amplitudes recorded at the highest 
luminance of 20 cd.s/m2, and for the b-wave also at 10 cd.s/m2 (Figure 11). These results 
indicate that miR-204 overexpression exerts a protective effect in RHO-P347S mice even when 
the vector is administered at a stage in which the degeneration is ongoing. Taken together, 
these data strongly corroborate my initial hypothesis that miR-204 overexpression by 








Figure 11. Protective effect of miR-204 subretinal injection at PN24 in RHO-P347S mice. 
ERG analysis at PN60 of RHO-P347S mice (n=11) injected subretinally at PN24 with the AAV.CMV.miR204 and 
control vector. Significantly improved a- and b-wave responses were recorded in the miR204-treated eyes 




Dissection of the molecular and cellular mechanisms underlying the 
protective effect of miR-204 overexpression in RHO-P347S mice 
 Histological analysis was previously performed at PN30 on retinas of both Aipl1-/- and RHO-
P347S mice injected with AAV.CMV.miR204 at PN4 to determine the structural and cellular 
changes associated with the observed protective effect (177). These experiments revealed a 
preservation of photoreceptor structures in the eyes injected with AAV.CMV.miR204 
compared to the contralateral control eyes, as assessed by immunolabelling for photoreceptor 
markers (i.e. Rhodopsin, Cone arrestin, M- and S-opsin) (177). In parallel, TUNEL staining 
revealed a significant decrease in the number of apoptotic cells in the outer nuclear layer (ONL, 
containing the nuclei of cone and rod photoreceptors) of miR-204-treated eyes. Moreover, 
71 
 
there was a reduction in gliosis as indicated by immunolabelling for glutamine synthetase 
(GS6), which is a commonly used marker for Müller glia cells (177).  
Photoreceptor cell death and reactive gliosis are tightly linked with the pathogenesis and 
progression of IRDs, even though their precise contribution is not fully elucidated. In particular, 
microglia activation is triggered by PR death in order to promote restoration of the retinal 
milieu. However, if the harmful stimulus is severe or sustained, activated microglia exceed the 
homeostatic activity and contribute to the worsening of the degeneration(188). Microglia 
activation was also shown at pre-degenerative stages (41, 189) indicating a possible role in the 
initiation of retinal degeneration processes. 
In this respect, the preservation of retinal function that we observed in RHO-P347S mice upon 
overexpression of miR-204 under the ubiquitous CMV promoter could derive either from a 
direct protective effect of miR-204 on PR cells or an indirect protection of PRs following the 
reduction of glial activation, or a combination of the above. To elucidate the mechanism by 
which miR-204 overexpression exerts its protective effect in RHO-P347S retinas, I sought to 
dissect the underlying molecular pathways and cellular processes. 
 
3.3 Transcriptome analysis of AAV.miR204-injected RHO-P347S mice 
To decipher the pathways that primarily mediate the protective effect observed upon 
subretinal administration of miR-204 in RHO-P347S mice, I carried out a transcriptome analysis 
in collaboration with the bioinformatic core at TIGEM. The RHO-P347S mice (n=3) were 
injected at PN4 that was shown to be an effective timepoint of injection. In each animal, one 
eye was injected with the AAV.CMV.miR204 and the contralateral eye was injected with the 
control vectors. Total RNA was collected from injected retinas at PN12 and was analysed by 
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RNASeq. I chose to carry out this experiment at PN12 in order to get insights into the early 
gene expression changes associated with miR-204 overexpression and avoid readouts of 
secondary effects that may merely reflect the differential evolution of the degeneration 
processes in RHO-P347S mice.  
Analysis of the transcriptomic data revealed a total of 420 Differentially Expressed Genes 
(DEGs) (based on a False Discovery Rate (FDR)<0.1) between the miR-204-injected eye versus 
the contralateral one. Of those, 104 genes were up-regulated and 316 genes were down-
regulated. A Gene Ontology Enrichment Analysis (GOEA) analysis was conducted on the DEGs, 
focusing on the biological processes (BP) terms (GOTERM_BP_FAT) with an enrichment score 
(ES) > 1.5 and FDR < 0.1.  
The top statistically significant enriched terms were mostly associated with the down-
regulated genes. Specifically, more than half of enriched terms were related to immune 
response, innate immune response, and inflammatory responses (Figure 12). On the other 
hand, there was significant enrichment for terms associated with visual perception among the 
up-regulated genes. This was in agreement with the improvement of ERG responses and the 
preservation of PRs morphology that I observed in the functional and histological analysis 





Figure 12. Top enriched biological processes (BPs) in RHO-P347S retinas injected with AAV.CMV.miR204. 
Among the differentially expressed genes up-regulated genes are significantly enriched for the visual perception 
BP (red). Down-regulated genes are significantly enriched for BPs related to innate immune response, 
inflammatory response, defense response, and cell death, among others (green). Terms that are directly related 
to the ancestor terms of “immune system process” (GO:0002376) and “response to stimulus” (GO: 0050896; 
ancestor of inflammatory response-related terms) are indicated in bold fonts. Terms are ranked according to the 
enrichment score of each cluster (plotted on the x axis) 
 
Interestingly, previous transcriptomic analyses of retinas from WT (C57BL/6) and RHO-P347S 
mice had shown that the pathways of innate immune response, inflammatory responses and 
cell death are associated with the early pathogenic events in RHO-P347S mice (M. Karali, 
personal communication).  
Taken together, these results strongly indicate that the subretinal administration of 
AAV.miR204 exerts a protective effect in RHO-P347S mice by reducing the activation of 
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processes such as immune response and cell death which are both associated with the onset 
and progression of retinal degeneration in this model. 
 
3.4 Identification and in vitro validation of mRNA targets underlying the protective 
effect of miR-204 in RHO-P347S mice: Siglec1 and Xaf1  
In order to uncover the possible direct mediators of the protective activity exerted by miR-204 
in RHO-P347S mice, I filtered the significantly down-regulated DEGs for genes that are 
predicted targets of miR-204.  
Several bioinformatic tools have been developed to predict miRNA-mRNA interactions (190). 
Most target prediction tools take into account common features of miRNA target recognition 
such as: a) a match between the seed sequence of a given miRNA and the 3’ UTR sequence in 
the mRNA of the putative target gene; b) the conservation across species of the regions of 
interest in the miRNA and mRNA sequences; c) the stability of the predicted miRNA-mRNA 
binding (assessed in terms of free energy, ΔG) and d) how easily the miRNA can access the 
interaction site of the target mRNA, given the secondary structure acquired by the mRNA 
(190). Based on these criteria, putative mRNA targets for a given miRNA are listed in databases 
(e.g. microTCDS (191), 
http://diana.imis.athenainnovation.gr/DianaTools/index.php?r=microT_CDS/index ; 
TargetScan (192), http://www.targetscan.org/). Other co-expression-based tools for 
systematic miRNA target recognition, such as HOCTAR (193) and Co-expression Meta-analysis 
of miRNA Targets (CoMeTa) (194), allow a more comprehensive and accurate prediction of 
miRNA targets.  
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I combined the miR-204 predicted targets from sequence-based miRNA target-prediction 
databases (e.g. microTCDS and TargetScan) and co-expression-based tools (e.g. Cometa), and 
identified a list of putative miR-204 targets among the genes that were down-regulated upon 
miR-204 administration in RHO-P347S. I then focused my attention on genes that were 
reported in literature to be associated with retinal degeneration and that were significantly 
up-regulated in RHO-P347S mice compared to WT mice, according to the transcriptomic 
analysis that was previously performed by our research group (see above). In particular, I 
selected two candidate genes, namely Siglec1 and Xaf1, and performed a luciferase assay to 
test whether miR-204 is able to directly target their 3’ UTR. 
 
Siglec1 is a predicted target of miR-204 (according to both microTCDS and TargetScan) and was 
up-regulated in retinas of RHO-P347S compared to WT mice. Upon miR-204 administration in 
RHO-P347S, Siglec1 was significantly down-regulated compared to the control-treated eye. 
Siglec1 encodes for Sialoadhesin (Sn or CD169), a cell adhesion receptor expressed on the 
membrane of macrophages and activated monocytes (195, 196). Siglec1 was recently shown 
to promote the neuroinflammation associated with the progression of neurodegenerative 
diseases and its up-regulation was related to the pathogenesis of neuronal ceroid 
lipofuscinosis (CLN) (197). Consistently, Siglec1 inactivation in a CLN mouse model resulted in 
a significant reduction of the neuron loss and the retinal thinning associated with the disease 
(197). Based on this evidence, I hypothesized that miR-204 may exert a beneficial effect on 




Xaf1 (XIAP-associated factor 1) is another predicted target of miR-204 that drew my attention. 
XAF1 is a proapoptotic factor that can sensitise cells to death by inhibiting the anti-apoptotic 
action of XIAP (198, 199) or sensitising the cell todeath triggers such as TNF-alpha, 
independently of its interaction with XIAP (199). Notably, XIAP is reported to be a protective 
factor in mouse models of IRDs (200, 201). I therefore hypothesized that the reduction of Xaf1 
levels could be a direct mechanism underlying the protective effect of miR-204 in RHO-P347S 
mice. Indeed, Xaf1 levels are higher in RHO-P347S compared to WT retinas, suggesting its 
involvement in retinal degeneration, similar to what had been observed for Siglec1. 
 
To test the direct binding of miR-204 to the 3’UTR of Siglec1 and Xaf1 I performed a luciferase 
assay which is routinely used to study the post-transcriptional activity of miRNAs on target 
genes (202). This assay consists in using the firefly luciferase (LUC) as a bioluminescent reporter 
gene fused with the 3′ UTR of the miRNA putative target gene. The engineered vector is then 
co-transfected with the test miRNA or negative controls in an in vitro cellular system. A 
reduced bioluminescence in the cells transfected with the test miRNA compared to those 
receiving the negative control miRNAs will indicate that the miRNA can bind to the 3’ UTR of 
engineered luciferase vector and regulate its expression. 
For this purpose, the 3’ UTR sequences of Siglec1 and Xaf1 were amplified by PCR from mouse 
genomic DNA and cloned downstream of the luciferase coding sequence in the luciferase 
reporter constructs. The so-engineered reporter construct was then co-transfected with the 
miR-204 mimic duplex into HeLa cells. Non-targeting miRNA mimics (negative mimic) were 
used in parallel as negative controls. In each experiment, a reporter construct containing the 
3’ UTR with the mutated predicted binding site of the miR-204 seed were used as control for 
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the specificity of the binding between the 3’ UTR and the miRNA mimics (Figure 13B). The 
presence of the mutated binding site should prevent the targeting of the 3’ UTR by the miRNA 
under investigation and consequently the reduction of luciferase activity. 
 
Figure 13. Schematic representation of the luciferase reporter vectors used for the transfection of HeLa cells 
and interaction with miR-204. 
A) The 3’ UTR of the putative target gene is inserted in the LUC vector. The direct binding between miR-204 and 
the miR-204 binding site in the 3’ UTR will lead to a reduced LUC expression and activity in the cells co-transfected 
with the luciferase (LUC) vector bearing the WT 3’ UTR of the gene and miR-204 mimics compared with the control 
cells (transfected with the engineered LUC vector and negative mimic). The intensity of the cellular bioluminiscent 
signal is used as a read-out of the LUC activity. 
B) To demonstrate the specificity of the binding between the 3’ UTR and the miR-204 mimics, together with miR-
204 or control miRNAs, the cells are transfected with a LUC vector bearing the 3’UTR of the putative target gene 
mutated for the miR-204 binding site. The specific binding between miR-204 and its binding site will be prevented 
and the LUC expression and activity will be comparable with that of control cells. 
 
I observed a significant reduction of luciferase activity of nearly 40% in the case of Siglec1 and 
50% for Xaf1 when the reporter vectors containing the 3’ UTR of Siglec1 or Xaf1 were co-
transfected with the miR-204 mimics, compared to the negative control non-targeting mimics 
(Figure 14 and Figure 15, bars on the left hand-side). Furthermore, the specificity of the miRNA 
seed:target site binding was confirmed by the fact that the luciferase activity was not reduced 
upon co-transfection of the mimics with the reporter vectors containing the mutagenized 
3’UTR of the gene of interest (Figure 14 and Figure 15, bars on the right hand-side). These 
miR-204 binding site 
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results confirmed both Siglec1 and Xaf1 as direct targets of miR-204. Therefore, it is plausible 
that the down-regulation of these two genes contributes to the protective effect exerted by 
miR-204 administration in RHO-P347S mice. In particular, the modulation of Xaf1 levels and its 
downstream impact on anti-apoptotic processes may account for an early protective effect 
exerted by miR-204 on photoreceptor survival directly. 
Moreover, the validation of Siglec1 as a target of miR-204 is in agreement with the early 
modulation of pathways related to inflammation and immune response observed in miR-204 
treated RHO-P347S mice. Together, these observations support a possible direct effect of miR-
204 on inflammatory processes such as microglial activation, which was shown to contribute 
to retinal degeneration even prior to PRs cell death (41). A direct modulation of this 
detrimental response may account for an additional, non PR-autonomous, mechanism 




Figure 14. miR-204 binds directly the 3’ UTR of Siglec1. 
79 
 
Luciferase assay confirms the direct binding of miR-204 to the 3’ UTR of Siglec1. miR-204 mimics (bars on the left 
hand-side) and negative control mimics (bars on the right hand-side) were transfected in HeLa cells together with 
the indicated luciferase reporter plasmids carrying either the WT Siglec1 3’ UTR (pTK-LUC-Siglec1 3’UTR) or the 
mutated binding site of the miR-204 seed (pTK-LUC-Siglec1 3’ UTR mut). Relative luciferase activity is reported as 
fold change to the cells transfected with control or miR-204 mimic. A two-way ANOVA was used to compare the 




Figure 15. miR-204 binds directly the 3’ UTR of Xaf1. 
Luciferase assay confirms the direct binding of miR-204 to the 3’ UTR of Xaf1. miR-204 mimics (bars on the left 
hand-side) and negative control mimics (bars on the right hand-side) were transfected in HeLa cells together with 
the indicated luciferase reporter plasmids carrying either the WT Xaf1 3’ UTR (pTK-LUC-Xaf1 3’ UTR) or the 
mutated binding site of the miR-204 seed (pTK-LUC-Xaf1 3’ UTR mut). Relative luciferase activity is reported as 
fold change to the cells transfected with control or miR-204 mimic. A two-way ANOVA was used to compare the 
groups. Data are represented as mean ± SEM. n=6 observations with * p<0.05 
 
 
3.5 miR-204 overexpression dampens microglia activation in vivo and in vitro 
The transcriptomic analysis described in section 3.3 revealed an extensive effect of miR-204 
on biological processes related to inflammatory and innate immune responses in RHO-P347S 
retinas. Resident microglia are the main effector cells of the innate immune system in the 
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retina, as elsewhere in the CNS (203). Resting microglia are mainly located in the inner retina 
and have a highly ramified morphology. Upon harmful stimuli such as oxidative stress, high 
intensity light and inherited mutations in retinal genes (48), microglia are activated, acquire a 
less ramified, amoeboid shape and migrate to the site of damage. Activated microglia have an 
enhanced phagocytic capacity, which is important for the removal of cell debris, and release 
pro-inflammatory cytokines, ROS and reactive nitrogen species (RNS) as well as 
neuromodulatory factors promoting tissue repair (32, 203). However, under excessive or 
prolonged pathological stimuli, activated microglia exceed their homeostatic function 
secreting a large amount of pro-inflammatory and potentially cytotoxic compounds (e.g. TNF-
α, IL-1β, ROS, NO) (36, 203). Several lines of evidence suggest that a prolonged or excessive 
microglial activation can contribute to the initiation and/or exacerbation of retinal 
degeneration in IRDs. For example, in a mouse model of RP, microglia were shown to infiltrate 
the ONL early during degeneration and phagocytose non-apoptotic, living rod photoreceptors 
thus accelerating photoreceptor loss and disease progression (41, 189).   
Based on these observations, I assessed whether miR-204 overexpression modulates microglia 
activation. I looked at the activation status of microglia by IF in PN30 retinas of RHO-P374S 
mice injected at PN4 with the AAV.CMV.miR204 vector. I performed a double-immunolabeling 
for the microglial marker Iba1 (Ionised calcium binding adaptor molecule 1), which marks both 
resting and activated microglia, and the CD68 lysosomal marker which is expressed at high 
levels in activated microglia. Immunolabeling of Iba1 in control-treated eyes revealed that the 
majority of microglial cells had an amoeboid shape and were mostly located in proximity to 
the photoreceptor outer segment (PR OS) (Figure 16, upper panels). Moreover, these bloated 
cells (arrowheads in Figure 16) close to the PR OS stained positive for CD68. Both the 
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morphology, spatial location and CD68-positivity indicated that these cells were mostly 
activated mononuclear phagocytes. On the contrary, the majority of microglial cells in miR-
204-treated eyes were ramified, confined to the inner retinal layer and stained weakly for 
CD68, suggesting that microglial activation was reduced compared to control-treated eyes. 
These results suggest that the administration of miR-204 in RHO-P347S mice dampens 
microglia activation and are in agreement with the transcriptomic analysis (paragraph 3.3) that 
had indicated an early impact of miR-204 on immune responses. Nevertheless, I cannot 
ascertain whether the effect of miR-204 on microglial cells is direct. 
 
 
Figure 16. AAV-Mediated Delivery of miR-204 reduces microglia activation in RHO-P347S mice. 
Immunofluorescence staining for the microglia markers Iba1 (green) and CD68 (red) on PN30 retinal sections of 
RHO-P347S mice injected with AAV.CMV.miR204 vector mix (1 x 109 GC AAV.CMV.miR204 and 1 x 108 GC 
AAV.CMV.EGFP) at PN4. The contralateral eye was injected with the AAV.CMV.EGFP control vector (1.1 x 109 
GC). Iba1-positive and CD68-positive, large-bodied amoeboid mononuclear phagocytes at the proximity of the 




To determine whether miR-204 is able to directly modulate microglial activation at the cellular 
level, I employed an in vitro approach based on the LPS-activated BV-2 microglial cells. BV-2 
cells are an immortalised murine microglia cell line and their activation by the bacterial 
endotoxin LPS is a widely used in vitro model to study neuroinflammation. The suitability of 
this model was corroborated by transcriptional analyses that showed a striking correlation 
between the BV-2 response to LPS and the in vivo LPS-mediated microglia activation (204). 
Overall, this cell line exhibits a response to inflammatory stimuli (like the LPS-induced one) and 
cytokines (e.g. interferon) that resembles the response of primary microglia (204). In 
particular, activated BV-2 cells show a normal regulatory response of the production of nitric 
oxide (NO), which is a key trigger of neuronal death in neurodegenerative processes (34). To 
get insights into the role of miR-204 in microglia activation, I assessed the effect of miR-204 
overexpression on the response of BV-2 cells to LPS treatment. For the cellular delivery of miR-
204, I generated two constructs using as backbone the psiUx expressing vector, which is 
particularly effective for the production of small non-coding RNAs (180). One vector, referred 
to as 'miR-204' in Figure 17 and 18, carried the precursor sequence of miR-204. The other 
vector, referred to as 'miR-204-mut' in Figure 17 and 18 contained the precursor of miR-204 
bearing a mutation in the seed sequence. 
Briefly, as shown in Figure 17, I transfected the BV-2 cells with the miR-204 and miR-204-mut 
constructs and then measured by qPCR in the LPS-activated BV-2 cells the levels of the 





Figure 17. Experimental set-up to test the effect of miR-204 delivery on the LPS-mediated microglia activation. 
 
 
Following LPS-induced activation for 24 h, iNOS was up-regulated seven-fold compared to 
untreated cells. I observed a statistically significant reduction of almost 50% in the mRNA levels 
of iNOS in cells transfected with miR-204 compared to those transfected with the control 
vector (Figure 18A). Across the experiments, I also observed a consistent, albeit not statistically 
significant, trend of reduction in the levels of TNF-α, a fundamental molecule for the induction 
and maintenance of inflammatory immune responses (33) (Figure 18B).  
 
Figure 18. Expression levels of inflammatory mediators following LPS-mediated activation in BV-2 cells 
transfected with miR-204. 
The expression level of TNF-α and iNOS was determined by quantitative real-time PCR and calculated as relative 
quantity (RQ) using as calibrator condition the untreated cells (light grey bars). A decrease in the expression was 
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observed in BV-2 cells transfected with the pre-miR204 vector (labelled 'miR-204') and activated with LPS 
compared to BV-2 transfected with pre-miR204-mutated vector (labelled 'miR-204 -mut') and activated with LPS. 
A one-way ANOVA followed by Tukey post-hoc analysis was used for within-groups analysis. Data are mean 
RQ ± SEM. * p<0.03 ***p<0.001. n=4 observations. 
 
 
This finding indicates that miR-204 delivery reduces the production of the aforementioned pro-
inflammatory mediators, probably by dampening the microglial activation that instead induces 
it. This observation is particularly relevant since both the free radical NO, which is produced by 
iNOS, and TNF-α are detrimental factors that contribute to retinal degeneration (33, 34, 48). In 
fact, treatments able to reduce their expression were shown to ameliorate photoreceptor death 
(34, 205). Therefore, it is plausible that the neuroprotection exerted by miR-204 in RHO-P347S 
may be mediated in part by a reduction of the inflammatory mediators produced by reactive 
microglia that, in turn, exacerbate photoreceptor damage (37). In light of the above, it will be 
interesting to test whether the microglial-specific delivery of miR-204 in RHO-P347S retinas 
improves retinal function. However, transduction of microglial cells by AAV vectors is still 
particularly challenging with only one study reporting a successful outcome (206). 
 
3.6 Photoreceptor-specific delivery of miR-204 partially preserves visual function in 
RHO-P347S mice  
 
To understand whether miR-204 preserves visual function in RHO-P347S mice by acting 
directly on PRs, I assessed the effect of delivering miR-204 using a rod-specific promoter. To 
this end, I generated the pAAV.RHO.miR204 vector by replacing the CMV promoter in 
pAAV.CMV.miR204 (used in the previous experiments) with the human RHO promoter 
sequence which directs transgene expression primarily to rod photoreceptors. I then used the 
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pAAV.RHO.miR204 construct to generate the corresponding AAV vector (AAV.RHO.miR204) in 
the 2/8 serotype, similar to what described for AAV.CMV.miR204. In this set of experiments, 
RHO-P347S mice were injected with the RHO.miR204 vector mix (1 x 109 GC AAV.RHO.miR204 
and 1 x 108 GC AAV.RHO.EGFP) in one eye, while the contralateral eye was injected with the 
control vector AAV.RHO.EGFP (1.1 x 109 GC). The subretinal injections were performed at PN4 
and PN14. Retinal function was assessed by ERG at PN30 and PN60.  
We recorded a significantly improved b-wave amplitude, both at PN30 and PN60, following 
injection of AAV.RHO.miR204 in the RHO-P347S mice at PN4. In particular, the b-wave 
amplitude of both scotopic and photopic ERG responses at PN30 was significantly higher in 
AAV.RHO.miR204-treated mice compared to those injected with the control (Figure 19B). 
Similar levels of retinal function persisted up to 2 months post-injection in miR-204 treated 
eyes and were significantly different compared to those of control eyes at most luminance 
stimuli applied (Figure 19CD). A-wave amplitudes also showed a trend of improvement in 
miR204-treated eyes, but without statistical significance.  
On the contrary, the subretinal delivery of AAV.RHO.miR204 at PN14 did not preserve 
significantly ERG responses at PN30 or PN60 (Figure 20), indicating that a PR-autonomous 
mechanism may not represent the primary mechanism underlying the protective effect 




Figure 19. Rod-specific delivery of AAV-miR-204 in the retina of RHO-P347S mice at PN4 improves ERG 
responses. 
ERG responses of RHO-P347S mice injected with AAV.RHO.miR204 or AAV.RHO.EGFP at PN4. Mice were recorded 
at PN30 (n = 19; A and B) and PN60 (n = 11; C and D). Subretinal injection of RHO.miR204 results in a statistically 
significant increase of b-wave amplitudes in miR204-treated eyes compared to control-injected contralateral 
eyes. Statistical significance (p value), calculated using an unpaired t test against control vector values, is indicated 








Figure 20. AAV-mediated delivery of miR-204 using a photoreceptor-specific promoter at PN14 does not 
improve ERG responses in RHO-P347S mice. 
ERG responses of RHO-P347S mice injected with the AAV.RHO.miR204 and the control vector (AAV.RHO.EGFP) at 
PN14. ERGs were recorded at PN30 (n=17; A) and PN60 (n=5; B). No statistically significant improvement of a- 
and b-wave amplitudes was recorded at PN30 and PN60 in RHO.miR204-treated vs contralateral control eyes. 
Vector doses were: 1x109 GC AAV.RHO.miR204, 1x108 GC AAV.RHO.EGFP per eye; 1.1x109 GC AAV.RHO.EGFP 
per control eye. 
 
In summary, the miR-204 overexpression under a rod-specific promoter at PN4 preserved 
retinal function in RHO-P347S mice, yet to a lesser extent than the one achieved upon the 
widespread delivery of miR-204 using the ubiquitous CMV promoter. Furthermore, IF analysis 
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and TUNEL assays did not reveal evident differences in the expression of PR markers (i.e. cone 
arrestin, Rhodopsin, M-opsin, S-opsin) and in the extent of cell death between RHO.miR204-
injected and control eyes (data not shown). Taken together, these data suggest that the 
protective effect exerted by AAV-miR204 delivery in RHO-P347S mice is only partially mediated 
by cell-autonomous mechanisms in photoreceptor cells. Instead, it is plausible that miR-204 
targets additional cell processes related to the pathogenesis of retinal degeneration in RHO-
P347S mice. In this respect, I did not detect any significant change in microglia activation (IF 
with anti-CD68 and anti-Iba1; data not shown) following RHO.miR204 delivery between 
miR204-treated and control eyes. This observation supports our interpretation that the 
dampening of immune responses in CMV.miR204-treated eyes is likely to be due to the direct 










In vitro study to identify candidate miRNAs with a protective action on 
retinal degeneration  
3.7 Light-induced damage in 661W cells as an in vitro model of retinal degeneration 
To expand my investigation on the potential role of miRNAs in Gene Independent Therapies 
(GITs) for IRDs, I decided to identify additional candidates that can counteract retinal 
degeneration processes regardless of the disease-causing mutation. To this aim, I used an in 
vitro model based on light-induced damage in the 661W cone-like cells (23, 207) which  has 
been widely used to study photoreceptor degeneration (185). In order to test the activity of 
several miRNAs in parallel, I designed a high-throughput approach. 
First, I determined the most appropriate conditions for our experimental needs, such as the 
ratio between cell seeding density and final concentration of miRNAs, and illumination. For the 
pilot experiments, I used 96-multiwell plates which are easier to handle, and transfected non-
targeting mimics (negative mimics) which I then used as controls for the actual screening. I 
initially tested 25 nM and 50 nM of mimics, and opted for the lower concentration to gain a 
fine modulation without overloading the miRNA processing machinery. To set up the system, 
I exposed the 661W cells to intense white LED light (15000 lux) for 4 h in a dedicated incubator 
and assessed cell viability using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide tetrazolium (MTT) assay according to published protocols (185). I also verified that 
the temperature of the cell culture medium remained stable under such conditions (i.e. 
presence of light source in the incubator). As control, I used cells grown on a plate that was 
shielded from light and was kept in the same incubator with the light-exposed one to ensure 
identical conditions of temperature, CO2 and humidity. These tests showed that under these 
conditions I could obtain a reduction of 661W cell viability comparable to that reported in 
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literature (185). Specifically, the cell viability decreased by ~20% compared to the control cells 
in dark conditions (Figure 21). Other combinations of cell density and light exposure induced 
even higher damage (data not shown). I considered that this moderate damage was 
appropriate to reveal the fine modulation that I expected since I preferred to use a mild 










Figure 21. Cell death after 4 hours of light exposure of 661W cells transfected with negative mimics. 
Cells were transfected with 25 nM of negative mimics and cultured in a clear 96-well plate at a density of 
~2700cellsl/well. Cell viability was assessed by an MTT assay. The absorbance readings of the blue formazan 
product were carried out at 570 nm and plotted as percent ratio of the light-exposed cells to the dark-grown ones 
(mean± SEM), set as 100% viable.  






3.8 High-content screening of a miRNA mimic library using the light-induced damage 
model 
To test the effect of a large number of miRNAs on the viability of 661W cells exposed to light 
stress I implemented a high-content screening approach in collaboration with Medina’s 
research group at TIGEM. The microscopy-based high-throughput screen allowed us to 
visualize and better control key features of the sample preparation (e.g. cell density, spatial 
distribution into the well) that could impact the screening efficiency and outcome. Moreover, 
the high-content approach enabled the simultaneous, automated and robust analysis of 
multiple phenotypic parameters within a single experiment. For the screening, I used a 384-
well format library of human miRNAs (miRIDIAN miRNA Mimic Library, Dharmacon) which 
contains mimics for every human miRNA annotated in the miRBase sequence database v.21.0. 
I then screened the first two plates of the library which contain 560 miRNAs, highly conserved 






Figure 22. Workflow for the high-content screening of a miRNA library based on light-induced damage in 
661W cells. 
 
3.8.1 Assay development: adaptation of the in vitro system (i.e. light-induced damage 
in 661W cells) and transfection conditions 
The high-content screening was developed in 384-well plates. Compared to the 96-well plates 
used in the pilot assay, the 384-well format reduces the inter-plate variability given that a 
larger number of test samples can be compared to each other within the same plate. 
Furthermore, the total amount of required reagent is significantly optimized. I therefore 
adapted the cell seeding density and the amount of transfection reagent used per well, 
accordingly. Adjusting the cell number (~ 650 cells/well) required various tests, because the 
bottom of the well in the 384-well black plates used for imaging has a different cell adherence 
•adaptation of the 661W light-damage system 
•transfection parameters 
•assay parameters (nuclear morphology)
Assay development 
(and adaptation)
• screening parameters (design)




•orthogonal assay to confirm the positive hitsHit confirmation
•assays to validate the mechanism of action of 
the positive hits




compared to the multi-well plates routinely used for cell culture. Moreover, I also extended 
light-exposure to 6 h to reach the same amount of cell damage achieved during the pilot 
experiments using the 96-well clear plates. Finally, using a non-targeting miRNA mimic 
transfection control labeled with Dy547 (absorbance/emission max: 557/570 nm), I verified 
that the average transfection efficiency was approximately 50% (Figure 23).  
 
 
Figure 23. Representative image of 661W cells transfected with microRNA mimic control Dy547. 
The cells were plated at the optimized conditions (650 cells/well, cultured for ~ 60 h in a 37°C and 5% CO2 
incubator), stained with Hoechst 33342 dye (shown in blue) and visualized under the high-content microscope. 
The red spots correspond to the signal of the red-fluorescent dye (Dy547)-labeled mimic. 
 
3.8.2 Assay development: assay parameters  
To assess the percentage of dying cells as a read-out of the damage induced by the light 
stimulus in 661W cells (transfected with control or test samples), I analysed the nuclear 
morphology using Hoechst 33342 staining in collaboration with Angela Panarella. Nuclear 
features (e.g. chromatin condensation, reduced nuclear size) were shown to be reliable 
indicators of dying cells (208, 209). Therefore, the quantitation of nuclear size and 
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condensation status using Hoechst 33342 staining is a straightforward assay of cell viability, 
particularly suitable for large-scale screenings. Hoechst is a fluorescent, non-intercalating dye 
that binds the A-T regions of the DNA minor groove. It penetrates both healthy and dying cells. 
However, its fluorescent intensity is increased due to nuclear condensation, a characteristic 
morphological change that occurs following cell injury.  
 
 
Figure 24. Hoechst 33342 staining of 661W cells transfected with negative mimics and kept in dark (dark) or 
exposed to light (light)). 
Representative images of wells from 384-format plates containing 661W cells transfected with negative mimics 
and kept in dark (dark) or exposed to light (light). The red arrows indicate nuclei with the typical morphology 
found in dying cells. Cells transfected with negative mimic controls and exposed to light show a higher frequency 






Figure 25. Boxplot showing the distribution of the nuclear parameters analysed for the control groups. 
The plots show a decrease of the mean nuclear area (A) and the increase of the mean fluorescence intensity (MFI; 
B) within the wells in dark (n=10) compared to those exposed to light (n=10), as expected for dying cells. *p <0.05, 
Mann-Whitney test 
 
To assess whether measurements of the nuclear area and Hoechst 33342 fluorescence 
intensity were suitable morphological readouts of the cell damage in our system, we looked at 
their mean values among the cells exposed to light-damage compared to those kept in the 
dark.  
We set thresholds (also validated by visual inspection) for nuclear size and Hoechst 33342 
staining intensity to define a subpopulation of dying cells (Figure 24). We then quantified their 
percentage in the overall population in each sample. The Columbus 2.6 software was then 
used for the automated analysis of the images acquired by the Opera HTS imaging system. The 
resulting analysis showed significant differences between the cells exposed to light-damage 












nuclear area (Figure 25A) as well as increased Hoechst fluorescence intensity (Figure 25B) in 
light-exposed cells, indicating the prevalence of a phenotype typical of damaged cells. 
The experimental setting used for the HCS experiments is recapitulated in Figure 26. 
 
 
Figure 26. Schematic representation of the experimental set up used for the HCS experiments. 
The HCS experiments consisted of the following stages. A) 661W (650 cell/well) were retro-transfected with 
miRNA mimics (25 nM) in a black 384-well plate with clear bottom which is adequate for imaging. B) The cells 
were exposed to light in dedicated humified incubator (37 °C, 5% CO2) containing a LED lamp placed on the 
bottom. The plate laid on a plexiglass plane that was placed above the lamp at such a distance so that the plate 
was reached by an illumination intensity of 15000 lux. The first two column of the plated where shielded to 
generate the controls in dark conditions. C) Following 6 h of light-exposure, Hoechst 33342 was added to the 
media and the cells were imaged by using the Opera live imaging system to assess changes in nucleus area and 
MFI. 
 
3.8.3 Primary screening: quality control (QC) of the assay  
Assessing assay performance is a fundamental prerequisite for the up-scaling of an in vitro 
assay. For this reason, quality control (QC) criteria have been defined to evaluate the 
performance of the controls and inform about the variability and reliability of the results. In 
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parameter for miRNA screenings (210). It evaluates the degree of difference between positive 
and negative controls considering also their variability, with a solid probabilistic and statistical 
interpretation. According to the SSMD equation (Figure 27), an SSMD value of 1, 2, or 3 
indicates that the probabilities that a value from the positive control population is greater than 
a value from the negative control population are respectively about 0.5, 0.95, and 0.975, when 
the difference shows a symmetric unimodal distribution with finite variance (211). This defines 
good quality for an assay with controls of moderate strength.  
 
Figure 27. Equation of the SSMD parameter. 
 
To perform the QC assay I considered the percentage of dying cells in the wells exposed to light 
(positive control , Cpos) or in dark conditions (negative control, Cneg). The resulting SSMDs of 
each replicate ranged between 2 and 3, indicating the good quality of the assay. 
 
3.8.4 Primary screening: screening parameters and hit identification 
I screened a subset of the human miRIDIAN mimic library consisting of the first 560 miRNAs 
that are among the most conserved across evolution (Figure 28). The screen was performed 
using 384-well plates in which the test miRNAs were arranged in the same positions as in the 
original 384-well plate of the library. The two first and the two last columns of the plate were 
used to test control conditions (Figure 29). In particular, the two first columns of each plate 
contained an equal quantity of 661W cells transfected with the negative mimics and shielded 
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from light to represent controls kept in dark conditions (Figure 29). The rest of the plate was 
exposed to light. The last two columns contained the 661W cells transfected with the negative 
mimics and were used as controls of cell death upon light exposure (Figure 29). Controls of 
transfection efficiency were also added in each control column. 
 
miRNA mature name 
let-7a-3p, let-7d-3p, let-7e-3p, let-7f-2-3p, let-7g-3p, let-7i-3p, miR-7-1-3p, miR-7-2-3p, miR-7-5p, 
miR-9-3p, miR-9-5p, miR-10a-3p, miR-10a-5p, miR-10b-3p, miR-10b-5p, miR-15a-3p, miR-15b-3p, 
miR-16-1-3p, miR-16-2-3p, miR-18a-5p, miR-18b-3p, miR-18b-5p, miR-19a-3p, miR-19a-5p, miR-19b-
1-5p, miR-19b-2-5p, miR-19b-3p, miR-20a-3p, miR-20a-5p, miR-20b-3p, miR-20b-5p, miR-21-3p, 
miR-21-5p, miR-22-3p, miR-22-5p, miR-23a-3p, miR-23a-5p, miR-23b-3p, miR-23b-5p, miR-24-1-5p, 
miR-24-2-5p, miR-24-3p, miR-25-3p, miR-25-5p, miR-26a-1-3p, miR-26a-2-3p, miR-26a-5p, miR-26b-
3p, miR-26b-5p, miR-27a-3p, miR-27a-5p, miR-27b-3p, miR-27b-5p, miR-28-3p, miR-28-5p, miR-296-
3p, miR-296-5p, miR-299-3p, miR-29a-3p, miR-29a-5p, miR-29b-1-5p, miR-29b-2-5p, miR-29b-3p, 
miR-29c-3p, miR-29c-5p, miR-30a-3p, miR-30a-5p, miR-30b-3p, miR-30b-5p, miR-30c-2-3p, miR-30c-
5p, miR-30d-3p, miR-30d-5p, miR-30e-3p, miR-30e-5p, miR-31-3p, miR-31-5p, miR-32-3p, miR-32-
5p, miR-33a-3p, miR-33a-5p, miR-33b-3p, miR-34a-3p, miR-34a-5p, miR-34b-3p, miR-34b-5p, miR-
34c-3p, miR-34c-5p, miR-92a-1-5p, miR-92a-2-5p, miR-92a-3p, miR-93-5p, miR-95, miR-96-5p, miR-
98-5p, miR-99a-3p, miR-99a-5p, miR-99b-3p, miR-99b-5p, miR-100-3p, miR-100-5p, miR-101-3p, 
miR-101-5p, miR-103a-3p, miR-105-5p, miR-106a-3p, miR-106a-5p, miR-106b-3p, miR-106b-5p, 
miR-107, miR-122-3p, miR-122-5p, miR-124-3p, miR-124-5p, miR-125a-3p, miR-125a-5p, miR-125b-
1-3p, miR-125b-2-3p, miR-125b-5p, miR-126-3p, miR-126-5p, miR-127-3p, miR-127-5p, miR-128, 
miR-129-2-3p, miR-129-5p, miR-130a-3p, miR-130a-5p, miR-130b-3p, miR-132-3p, miR-132-5p, miR-
133a, miR-133b, miR-134, miR-135a-3p, miR-135a-5p, miR-135b-5p, miR-136-3p, miR-136-5p, miR-
137, miR-138-1-3p, miR-138-2-3p, miR-138-5p, miR-139-3p, miR-139-5p, miR-140-3p, miR-140-5p, 
miR-141-3p, miR-141-5p, miR-142-3p, miR-142-5p, miR-143-3p, miR-143-5p, miR-144-3p, miR-144-
5p, miR-145-3p, miR-145-5p, miR-146a-3p, miR-146a-5p, miR-146b-3p, miR-147a, miR-148a-3p, 
miR-148b-3p, miR-148b-5p, miR-149-3p, miR-149-5p, miR-150-3p, miR-150-5p, miR-151a-3p, miR-
151a-5p, miR-152, miR-153, miR-154-3p, miR-154-5p, miR-155-3p, miR-155-5p, miR-181a-3p, miR-
181a-5p, miR-181b-5p, miR-181c-3p, miR-181c-5p, miR-181d, miR-182-3p, miR-182-5p, miR-183-3p, 
miR-183-5p, miR-184, miR-185-3p, miR-185-5p, miR-186-3p, miR-186-5p, miR-187-3p, miR-187-5p, 
miR-188-3p, miR-188-5p, miR-190a, miR-191-3p, miR-191-5p, miR-192-3p, miR-192-5p, miR-193a-
3p, miR-193a-5p, miR-193b-3p, miR-193b-5p, miR-194-3p, miR-194-5p, miR-195-3p, miR-195-5p, 
miR-196a-3p, miR-196a-5p, miR-196b-5p, miR-197-3p, miR-198, miR-199a-3p, miR-199a-5p, miR-
199b-3p, miR-199b-5p, miR-200a-3p, miR-200a-5p, miR-200b-5p, miR-200c-3p, miR-200c-5p, miR-
202-3p, miR-203a, miR-204-5p, miR-205-5p, miR-206, miR-208a, miR-210, miR-211-5p, miR-212-3p, 
miR-214-3p, miR-214-5p, miR-215, miR-216a-5p, miR-217, miR-218-1-3p, miR-218-2-3p, miR-218-
5p, miR-219-2-3p, miR-221-5p, miR-222-5p, miR-301a-3p, miR-302a-3p, miR-302a-5p, miR-302b-3p, 
miR-302b-5p, miR-302c-3p, miR-302c-5p, miR-302d-3p, miR-302d-5p, miR-320a, miR-323a-3p, miR-
323a-5p, miR-324-3p, miR-324-5p, miR-325, miR-326, miR-328, miR-329, miR-330-3p, miR-330-5p, 
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miR-331-3p, miR-331-5p, miR-335-3p, miR-335-5p, miR-337-3p, miR-337-5p, miR-338-3p, miR-338-
5p, miR-339-3p, miR-339-5p, miR-340-3p, miR-340-5p, miR-342-3p, miR-342-5p, miR-345-5p, miR-
346, miR-361-3p, miR-361-5p, miR-362-5p, miR-363-3p, miR-365a-3p, miR-367-3p, miR-367-5p, miR-
369-3p, miR-369-5p, miR-370, miR-371a-3p, miR-371a-5p, miR-372, miR-373-3p, miR-373-5p, miR-
374a-3p, miR-374a-5p, miR-375, miR-376a-3p, miR-376b-3p, miR-376c-3p, miR-377-3p, miR-377-5p, 
miR-378a-3p, miR-378a-5p, miR-379-3p, miR-379-5p, miR-380-3p, miR-380-5p, miR-381-3p, miR-
382-5p, miR-383, miR-384, miR-409-3p, miR-409-5p, miR-410, miR-411-3p, miR-411-5p, miR-412, 
miR-421, miR-422a, miR-423-3p, miR-423-5p, miR-424-3p, miR-424-5p, miR-425-3p, miR-425-5p, 
miR-429, miR-431-3p, miR-431-5p, miR-432-3p, miR-432-5p, miR-433, miR-448, miR-449a, miR-
449b-5p, miR-450a-5p, miR-451a, miR-452-3p, miR-452-5p, miR-454-3p, miR-454-5p, miR-455-3p, 
miR-483-3p, miR-483-5p, miR-484, miR-485-5p, miR-488-3p, miR-490-5p, miR-491-3p, miR-492, 
miR-493-5p, miR-494, miR-495-3p, miR-496, miR-497-3p, miR-497-5p, miR-498, miR-499a-3p, miR-
499a-5p, miR-500a-3p, miR-500a-5p, miR-501-3p, miR-501-5p, miR-502-3p, miR-502-5p, miR-503-
5p, miR-504, miR-505-3p, miR-505-5p, miR-506-3p, miR-507, miR-508-3p, miR-508-5p, miR-509-3p, 
miR-509-5p, miR-512-3p, miR-512-5p, miR-513a-3p, miR-513a-5p, miR-515-3p, miR-515-5p, miR-
516a-5p, miR-516b-3p, miR-516b-5p, miR-517-5p, miR-517a-3p, miR-517b-3p, miR-517c-3p, miR-
518a-3p, miR-518a-5p, miR-518b, miR-518c-3p, miR-518c-5p, miR-518d-3p, miR-518d-5p, miR-
518e-3p, miR-518e-5p, miR-518f-3p, miR-518f-5p, miR-519a-3p, miR-519a-5p, miR-519b-3p, miR-
519b-5p, miR-519c-3p, miR-519c-5p, miR-519d, miR-519e-3p, miR-519e-5p, miR-520a-3p, miR-520a-
5p, miR-520b, miR-520c-3p, miR-520c-5p, miR-520d-3p, miR-520d-5p, miR-520e, miR-520f, miR-
520g, miR-520h, miR-521, miR-522-3p, miR-522-5p, miR-523-3p, miR-523-5p, miR-524-3p, miR-524-
5p, miR-525-3p, miR-525-5p, miR-526a, miR-526b-3p, miR-526b-5p, miR-527, miR-532-3p, miR-545-
5p, miR-548a-3p, miR-548a-5p, miR-548b-3p, miR-548c-3p, miR-548c-5p, miR-548d-3p, miR-548d-
5p, miR-549a, miR-550a-3p, miR-551b-3p, miR-555, miR-556-5p, miR-557, miR-558, miR-559, miR-
561-3p, miR-562, miR-563, miR-564, miR-566, miR-567, miR-568, miR-569, miR-570-3p, miR-571, 
miR-572, miR-573, miR-574-3p, miR-575, miR-576-5p, miR-577, miR-578, miR-579, miR-580, miR-
581, miR-582-5p, miR-583, miR-584-5p, miR-585, miR-586, miR-587, miR-588, miR-589-3p, miR-590-
5p, miR-591, miR-592, miR-593-3p, miR-593-5p, miR-595, miR-596, miR-597, miR-598, miR-599, miR-
600, miR-601, miR-602, miR-603, miR-604, miR-605, miR-606, miR-607, miR-608, miR-609, miR-610, 
miR-611, miR-612, miR-613, miR-614, miR-615-3p, miR-615-5p, miR-616-3p, miR-616-5p, miR-617, 
miR-618, miR-619, miR-620, miR-621, miR-622, miR-624-3p, miR-625-3p, miR-628-5p, miR-629-5p, 
miR-632, miR-633, miR-634, miR-635, miR-636, miR-637, miR-638, miR-639, miR-640, miR-641, miR-
642a-5p, miR-643, miR-644a, miR-645, miR-646, miR-647, miR-648, miR-649, miR-650, miR-651, 
miR-652-3p, miR-653, miR-654-3p, miR-654-5p, miR-655, miR-656, miR-657, miR-658, miR-659-3p, 
miR-660-5p, miR-661, miR-662, miR-663a, miR-668, miR-671-5p, miR-675-5p, miR-758-3p, miR-765, 
miR-766-3p, miR-767-3p, miR-767-5p, miR-769-3p, miR-769-5p, miR-770-5p, miR-802 
 
Figure 28. List of miRNAs used in the HCS. 
The table shows the 560 miRNAs that were screened in the HCS experiments. They represent a subset of the most 












Figure 29. Arrangement of the 384-well plate used for the assay. 
The test miRNAs were plated at the same position as in the original 384-plate of the miRNA library. Control 
columns contained 661W cells transfected with the negative mimics and the Dy547-labeled miRNA as control of 
the transfection efficiency. The upper and lower edge rows contained only medium and un-transfected cells to 
minimize medium evaporation within the wells of the adjacent test rows. 
 
 
In order to compare the effect of each miRNA treatment to control mimics, the percentage of 






Figure 30. Equation for calculating z score. 
Y = percentage of dying cells in the sample well; YN = percentage of dying cells in the negative mimic wells exposed 
to light; SDN = standard deviation of the percentage of dying cells in 661W transfected with neg mimic and 
exposed to light. 











I ranked the z score obtained for each miRNA and arbitrarily defined an average z score lower 
or equal to -2 as threshold (dashed red line in Figure 31). From this analysis, I selected the 
miRNAs that showed the lowest variability among replicates, namely miR-429 and miR-218-5p 
(depicted in red in Figure 31), as positive hits for further confirmation.  
Z score values equal or higher than 2 indicated miRNAs that exacerbated the percentage of 
dying 661W cells upon light exposure compared to the negative mimics (threshold indicated 
by the black dashed line in Figure 31). For instance, miR-9-5p was among the miRNAs that 
exacerbated the light-induced damage in 661W cells. Interestingly, miR-9 was found to be up-
regulated in the serum of patients with age-related macular degeneration (AMD) and has been 
proposed as a biomarker for AMD (141, 212). The retinal degeneration associated with AMD 
shares common mechanisms of cell death with the degeneration observed in the 661W cells 
exposed to light (i.e. ROS production). Therefore, the finding related to miR-9 corroborates the 

























Figure 31. Plot showing the outcome of the primary screening. 
The red dashed line indicates the threshold used to select the positive hits with a protective effect i.e. a z score < 
- 2 in at least two replicates. miR-429 and miR-218-5 (red arrows) are two positive hits. The diamonds above the 
black dashed line represent the miRNAs that exacerbated the light-induced damage in 661W compared to the 
control mimics, as indicated by z scores ≥ 2. miR-9-5p (black arrow) induced the highest degree of damage in 
661W cells exposed to light. 
 
 
3.8.5 Confirmation of positive hits  
To confirm the positive hits identified in the primary screening, it is essential to perform an 
orthogonal assay that relies on a detection technology different from that of the primary 






















with a spectrophotometric read-out using the set-up of the pilot experiments. For these 
independent validation experiments I used new batches of test miRNA mimics. I assessed the 
effect of each miRNA on the viability of the 661W cells exposed to light as a percentage of the 
viability measured for the 661W cells transfected with the corresponding miRNA and kept in 
dark (considered as 100% viable). 
The results of the MTT assay showed that the viability of 661W cells transfected with the 
negative mimics (ctl mimic) was significantly reduced (20%) after light exposure. Instead, the 
viability of 661W transfected with miR-218-5p or miR-429 did not show significant changes 
between the conditions of photo-stress or darkness (Figure 32).  
These data confirmed that both positive hits from the primary screening were able to 
counteract the light-induced damage in 661W. Therefore, these two miRNAs were further 












Figure 32. Confirmation of the positive hits from the primary screen using an MTT assay. 
An MTT assay was used to assess cell viability. Cell viability of 661W transfected with ctl mimic resulted 
significantly reduced after light exposure, while cell viability of 661W transfected with miR-218-5p and miR-429 
did not change significantly between dark and light conditions. These results showed that both the primary 
selected hits, miR-218-5p and miR-429 can protect the 661W cells from light-induced damage The absorbance 
readings of the blue formazan product were carried out at 570 nm and plotted as percentage of light-exposed 
cells relative to those kept in dark condition (mean± SEM), considered as 100% viable. The cells transfected with 
negative control mimics were referred to as 'ctl mimic'. *p<0.05 
 
3.8.6 Hit validation: miR-429 reduces ROS levels in 661W cells exposed to H2O2 
Reactive Oxygen Species (ROS) are radical and non-radical oxygen species whose excessive 
accumulation leads to molecular modifications of cellular components (e.g. protein oxidation, 
lipid peroxidation). These modifications can, in turn, result in dysfunction and severe damage 
(49, 50). Light-induced damage in the retina is tightly associated with the increase of ROS 
levels. In fact, ROS-induced oxidative stress is considered as a major player in the retinal 




to get insights into the possible mechanisms underlying the activity of the confirmed hits, I 
assessed the effect of miR-429 and miR-218-5p on the accumulation of intracellular ROS levels. 
To this end, 661W cells transfected with both miRNA mimics or negative control mimics were 
exposed to hydrogen peroxide (H2O2), a commonly used and well-characterized inducer of 
oxidative stress. By visual inspection under the light microscope, I first determined a dose of 
H2O2 and an exposure time (200 µM for 3 h and 15’) that induced a cellular morphology typical 
of stressed cells (e.g. reduced cell size), without causing extensive cell detachment and death. 
I then used the CM-H2DCFDA ROS sensor to detect intracellular ROS levels. CM-H2DCFDA 
passively diffuses into the cells where it undergoes cleavage by the intracellular esterase and 
oxidation resulting in a green fluorescent adduct that is retained inside the cell. To improve 
sensitivity, labeled cells were visualized by fluorescence microscopy using the Operetta live 
imaging system. The fluorescence levels and spatial distribution of the green signal were then 






Figure 33. ROS levels in 661W cells transfected with miR-429 did not increase significantly upon exposure to 
H2O2. 
The fluorescence and spatial distribution of the green signal emitted by the ROS-sensitive probe was quantified 
to assess ROS levels. The data are plotted as a ratio of H2O2-treated cells (dark grey bars) compared to untreated 
control cells (ctrl mimic; light grey bar) (mean ± SEM). A nonparametric test for the interaction in two-way 






Figure 34. 661W cells transfected with miR-429 show reduced fluorescence of the ROS-sensitive probe after 
treatment with H2O2. 
661W cells transfected with miR-429 or control mimics (ctl mimic) were treated with H2O2 (200 µM for 2 h 30 
min) and loaded with a ROS-sensitive probe (green fluorescent signal). Untreated cells (without H2O2) were used 
as controls. Cells were also stained with the DAPI nuclear dye (shown in blue). Images were acquired by using the 
Operetta live imaging system at a 20X magnification. 
 
I found that the 661W cells transfected with control mimics and exposed to H2O2 showed a 
significantly higher and more diffuse green fluorescence signal compared to untreated cells, 
indicating higher ROS levels (Figure 33; Figure 34, upper panel). In contrast, the cells 
overexpressing miR-429 showed a small increase in the green signal following H2O2 treatment 
compared to control cells, indicating low and non-significant ROS levels (Figure 33; Figure 34 
lower panels). Furthermore, the ROS levels in 661W cells transfected with miR-429 and treated 
with H2O2 were significantly lower compared to cells transfected with control mimics. On the 
contrary, the 661W cells transfected with miR-218-5p mimic still showed a significant increase 
of ROS levels upon treatment with H2O2. The visual inspection of the automatically acquired 
images corroborated the outcome of the above analysis (Figure 34). Taken together, these 














findings indicate that the transfection of miR-429 in 661W cells is able to control the increase 
of ROS levels, without resetting them completely. A plausible explanation could be that the 
overexpression of miR-429 prevents the excessive accumulation of ROS during photo-stress, 
while preserving a minimal ROS quantity that can elicit a potential antioxidant response (216) 
favoring cell protection.  
Additional secondary assays should be performed to study the effect of the selected miRNAs 
on concomitant pathological mechanisms associated with light-induced retinal damage. For 
example, evaluating the effect of miR-218 and miR-429 overexpression on Ca++ mobilization, 
mitochondrial features and adenosine triphosphate (ATP) levels after light exposure could 
provide valuable insights on the precise role of the selected protective hits (217). 
 
3.9 miR-429 overexpression enhances AMPK activation in 661W cells exposed to light 
damage  
To better characterise the protective effect of miR-429 overexpression against light-induced 
damage in 661W cells, I sought to identify the molecular pathways involved. After combining 
data from literature and miRNA target-prediction databases (e.g. microTCDS, TargetScan) I 
looked into a possible link between the activation of the adenosine monophosphate (AMP)-
activated protein kinase (AMPK) pathway and the effect of miR-429 in 661W cells exposed to 
light-induced damage. Recent studies demonstrated a role of AMPK activation in the 
neuroprotection and amelioration of visual activity in retinas under photo-stress (217, 218).  
In particular, while photo-stress reduced mitochondrial respiratory function and ATP levels, 
pharmacological activation of the AMPK pathway promoted neuronal survival and retained 
visual function, stabilizing ATP levels through the preservation of mitochondrial enzyme 
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activity (217).  Moreover, activated AMPK appears to be essential in maintaining the 
intracellular redox status, as emerged in endothelial cells, by inhibiting oxidant production 
from mitochondria, NADPH oxidases, etc. or by increasing the expression of antioxidant 
enzymes such as SOD2 (219).   
AMPK is ubiquitously expressed and is considered a key energy sensor, fundamental to 
maintain proper energetic cellular conditions during environmental stress. In particular, it 
monitors changes in ATP levels and increases the rate of ATP-producing pathways in response 
to an increase in adenosine monophosphate (AMP)/ adenosine diphosphate (ADP) relative to 
ATP (220). AMPK comprises a catalytic α-subunit associated with β and γ regulatory subunits. 
AMPK signalling is initiated by the binding of AMP to the AMPKγ subunit. It is positively 
regulated by phosphorylation of the amino acid Thr172 of its α-subunit, which is the major 
phosphorylation site of AMPK, and is negatively regulated by phosphatases (220). 
Interestingly, the catalytic subunit of the key AMPK phosphatase, namely PP2A, is a predicted 
and experimentally validated target of miR-429 (221). As a consequence, miR-429 could 
positively modulate the activation of AMPK pathway by reducing the expression of the catalytic 
subunit of PP2A (PP2Ac). 
Based on this evidence, I performed a western blot analysis to assess the levels of AMPK 
phosphorylation (Thr172) in 661W cells transfected with miR-429 or control mimics and either 
exposed to light for 6 h or kept in dark (Figure 35A). I observed a significant increase of the p-
AMPK/AMPK ratio in the 661W cells overexpressing miR-429 and exposed to light compared 
to the cells transfected with control negative mimic (ctl mimic) and kept in dark, thus indicating 
the activation of the AMPK pathway (Figure 35B).  
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It has also been reported that retinas exposed to photo-stress can generate an initial, transient, 
protective cellular response that subsequently declines, leaving the cell exposed to damage 
(217). Based on this theory, it would be tempting to hypothesize that the 661W cells 
transfected with control mimics and exposed to light-damage try to activate a pro-survival 
response, as suggested by the slight increase of p-AMPK levels. Instead, the miR-429 
overexpression appears to significantly strengthen and prolong the activation of AMPK pro-
survival pathway.  
 
Figure 35. Activation of the AMPK pathway in 661W cells transfected with miR-429 and exposed to light 
damage. 
A) Western blot (WB) analysis of total cell lysates from 661W cells transfected with negative control mimic (ctl 
mimic) or miR-429. Transfected cells were either kept in darkness or exposed to light-stress. Lysates were 
immunoblotted with antibodies to p-AMPKα (Thr 172), AMPK and p115.  
B) Optical densities (OD) of the bands from three independent experiments were quantified and plotted as mean 
± SEM. The 661W cells transfected with miR-429 and exposed to light damage showed a significant increase in 
the p-AMPK/AMPK compared to the cells transfected with the ctl mimic and kept in dark. ANOVA and multiple 

































To assess whether there is a link between the protective activity of miR-429 in light-injured 
661W cells and AMPK activation, I assessed the viability of the 661W cells transfected with 
miR-429 or control mimics and exposed to light after pharmacological inhibition of the AMPK 
activity. To this aim, I used the SBI-0206965 molecule which was shown to be a potent and 
more selective inhibitor of the AMPK activity compared to the commonly used Compound C 
(222).  
I did not find significant changes in viability between 661W cells transfected with miR-429 or 
control mimics and kept in dark, regardless of the SBI-0206965 treatment (data not shown). I 
then evaluated whether AMPK inhibition in 661W cells transfected with miR-429 or negative 
mimics could affect cell viability after 4 h of light exposure. I found that the inhibition of AMPK 
activity by SBI-0206965 at both tested concentrations (i.e. 1 µM and 5 µM) was associated with 
a reduction of viability upon light-exposure that resulted comparable to the one observed in 
the 661W transfected with control mimics in the absence of SBI-0206965 (Figure 36A). On the 
contrary, the transfection of 661W cells with miR-429 confirmed the ability of this miRNA to 
preserve cell viability upon light exposure (Figure 36B), as shown in the confirmation 
experiments of the primary hits (section 3.8.5). This response was not affected by SBI-0206965 
pre-treatment at the lower concentration tested (1 µM). Instead, when cells overexpressing 
miR-429 were treated with a higher concentration of SBI-0206965 (5 µM) and exposed to light, 
I detected a notable decrease of cell viability, suggesting that the AMPK activity contributes to 
the protective effect mediated by miR-429. Taken together, these data indicate that the 
protective effect of the miR-429 overexpression in this in vitro model of photo-stress is, at least 
in part, mediated by the activation of the AMPK pro-survival pathway. Our results are in 
agreement with recent studies that describe the activation of the AMPK pathway as a key 
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protective mechanism in mouse models of light induced damage (217, 218) and suggest a 
possible link between miR-429 and AMPK activation in different models involving oxidative 









Figure 36. Pharmacological inhibition of AMPK abolishes the protective effect of miR-429 in light-stressed 
661W cells 
The 661W cells transfected with negative mimics (ctl mimic) (A) or miR-429 (B) were pre-treated with the 
pharmacological inhibitor of AMPK activity (SBI-0206965) for 90 min prior to light exposure for 4 h. Cell viability 
was assessed by an MTT assay. The absorbance readings of the blue formazan product were carried out at 570 
nm and were plotted as percentage of light-exposed conditions compared to the dark control, considered as 100% 
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Finally, to understand whether the effect of miR-429 on AMPK activation could be mediated 
by the regulation of the gene that encodes PP2Ac, analysis of the transcripts, protein levels 






4 DISCUSSION AND CONCLUSIONS 
The results of the first part of my thesis work confirms our hypothesis that miR-204 is able to 
slow down retinal degeneration when administered at advanced stages of the disease in a 
relevant murine model of IRD, the RHO-P347S mice. I recorded a long-lasting improvement of 
retinal function upon subretinal delivery of miR-204 both at PN14 and PN24, when the adult 
retinas already exhibit signs of degeneration. The observed increase in the a- and b-wave 
amplitudes of the ERG response, albeit moderate, indicated a protective effect on rod and 
cone photoreceptor function as well as on the synaptic connectivity in the inner retina. Further 
enhancements could derive from testing higher vector doses and inoculations in multiple 
injection spots with the aim to increase the number of transduced cells. Importantly, the ability 
of miR-204 to preserve retinal function by injections after the disease onset supports the 
clinical potential of the approach at patient-relevant stages of disease progression. In that 
respect, it should be underlined that the effect of miR-204 was tested using a retinal delivery 
system with proven safety and efficacy for clinical use (i.e. by subretinal injection of AAV 
vectors carrying the sequence of interest). Further experiments using alternative IRD models, 
including larger animals, are needed to corroborate the clinical potential of the proposed 
approach.  
The use of a relevant murine model, like the RHO-P347S mice, enabled us to explore the 
pathways related to the miR-204 overexpression and the functional response associated with 
different timings of intervention in a significant number of animals. The latter aspect is indeed 
crucial for assessing the effect of novel treatments. The advantage of using larger animal 
models, instead, is that the eyes have similar size to the human one, thus allowing a more 
accurate testing of dosage studies and delivery routes. In addition, the structural composition 
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of the retina of larger animal models (e.g. rod:cone ratio in pigs) is more similar to that of 
humans. In RHO-P347S mice I did not detect significant morphological improvements at P30 
or P60 after injection of AAV.miR-204 vector at PN14 and PN24. Future experiments in larger 
animals that combine the aforementioned structural features with a longer life-span and a 
slower rate of degeneration, could better clarify the relation between functional and structural 
preservation following miR-204 delivery at advanced stages of degeneration.  
Dysregulated innate immune response and inflammation have emerged as relevant 
pathological processes associated with IRDs both in preclinical models (41) and patients(37, 
40). Importantly, their deleterious effect is common to various IRDs models bearing different 
disease-causing mutations. In particular, microglia activation represents a prominent non-cell 
autonomous pathological mechanism that accompanies different forms of IRDs (48).  
Microglia are the main immune effector cells in the CNS as well as in the retina. Their activation 
under conditions of tissue damage is fundamental to maintain the integrity of the retinal milieu 
by removing cell debris, promoting tissue repair and restoring homeostasis. However, when 
the triggering insult is excessive or prolonged, activated microglia contribute to the initiation 
and/or exacerbation of retinal degeneration in IRDs. They can phagocytose living PRs (41), 
proliferate and release a large amount of pro-inflammatory and potentially cytotoxic 
compounds  (35) (e.g. TNF-α, IL-1β, ROS, NO) that sustain the inflammatory processes leading 
to deleterious effects. Increased microglia proliferation and elevated levels of pro-
inflammation factors are associated with PR dysfunction and death not only during 
degeneration, but even at disease stages that precede PR degeneration (48). Protective 
approaches that are based on limiting microglia activation and innate immune response in IRDs 
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have indeed showed promising results. Such strategies should however be designed in a way 
that does not interfere with the homeostatic function of the retinal immune effectors. 
miRNAs are attractive therapeutic tools as they can control functionally correlated pathways 
allowing a fine-tuning of the related processes. In agreement with these principles, the results 
of our transcriptomic analysis indicated that miR-204 overexpression is able to influence 
multiple processes in RHO-P347S mice already at a pre-degenerative stage, particularly those 
related to the innate immunity and inflammatory responses. The modulation of these 
pathways, therefore, more likely represents a primary mechanism underlying the miR-204 
protective effect rather than an indirect response to reduced triggering signals from the 
degenerating PRs. In particular, our in vitro study suggested a direct activity of miR-204 on 
microglia activation in IRDs, taking into account the reduction of TNF-α and iNOS expression in 
BV-2 cells overexpressing miR-204 and exposed to LPS-mediated activation. Importantly, miR-
204 overexpression does not suppress completely the expression of these mediators, 
endorsing the possibility that miR-204 prevents the exacerbation of retinal damage mediated 
by microglia overactivation without suppressing completely their activity. To fully address this 
aspect, it will be interesting to test the effects of the microglial-specific delivery of miR-204 in 
RHO-P347S retinas. However, the transduction of microglial cells by AAV vectors is still 
particularly challenging with only one study reporting a successful outcome (206). 
Nonetheless, the administration of miR-204 under a ubiquitous promoter showed a stronger 
effect than the one obtained with the use of the rod-specific RHO promoter. This evidence 
supports the idea that the protective effect of miR-204 in IRD models is presumably due to the 
pleiotropic action of this miRNA on multiple cell targets (e.g. RPE, photoreceptors, microglia). 
Therefore, as also suggested by the in vitro evidence, the dampening of microglial reactivity 
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observed upon AAV.CMV.miR204 delivery is most likely due to a direct role of this miRNA on 
microglia activation rather than secondary to events occurring in PRs. 
It is known that miR-204 plays a pivotal role in retinal development and function, as well as in 
the pathogenesis of IRDs when mutated (169). The effects of modulating miR-204 expression 
in IRDs was never reported prior to a recently published study by the Banfi's research team 
(177). In the first part of my PhD thesis, which is included in the above-mentioned manuscript, 
I showed that miR-204 overexpression at post-developmental stages exert protective effects 
in a preclinical model of IRD, supporting its translational potential for the development of 
therapeutic approaches. In fact, both the described administration system (i.e. subretinal 
injection of AAV) and disease stage of intervention (i.e. PN24, advanced postnatal stages) were 
compatible with the development of a clinical protocol for human translational purposes (e.g. 
subretinal delivery in patients). In light of the effect of miR-204 on disease mechanisms 
common to genetically different IRDs, this miRNA can represent a mutation-independent 
therapeutic agent that dampens disease-amplifying processes.  
Strategies to halt or slow down the IRD progression irrespectively of the specific pathological 
mutation are particularly relevant to the development of therapeutic approaches intended for 
a large population of IRD patients. To date, the only treatment available on the market for IRDs 
is based on gene replacement therapy and destined to patients with an autosomal dominant 
form of LCA associated with mutations in RPE65. Considering that gene replacement strategies 
are not suitable for the treatment of dominant conditions due to the gain-of-
function/dominant-negative effects of the mutated allele, the gene-independent approach 
that I am pursuing with this study is particularly appealing. Eventually, it will be interesting to 
study the association of mutation-independent treatments based on miRNAs with gene-
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specific replacement approaches with the ultimate aim to improve their efficiency. Finally, it is 
worth exploring the therapeutic potential of the proposed strategy also in the context of 
multifactorial forms of retinopathies in which dysregulated innate immunity response exerts a 
pathogenic role (i.e. AMD and diabetic retinopathy). 
 
The results of the second part of my thesis suggest that the development of miRNA-based 
approaches for IRDs could be useful to modulate additional mechanisms that participate to 
the disease progression in a mutation-independent manner, such as oxidative stress. In 
particular, oxidative stress is considered a major contributor in the secondary cone demise 
that occurs during the progression of RP regardless of the disease-causing mutation (21). 
Oxidative stress occurs when the cell produces excessive oxidant agents that overwhelm its 
intrinsic capacity to neutralize them through endogenous antioxidants (52). ROS constitute a 
highly reactive oxidant species that is produced both as a by-product of cellular metabolism as 
well as by dedicated enzymes such as those of the NOX family (54). Oxidative stress leads to 
modifications of cellular components (e.g. protein oxidation, lipid peroxidation) that can, in 
turn, result in cell dysfunction (29, 223) and severe damage (49). However, it was 
demonstrated that low and controlled levels of ROS take part to physiological cell signalling 
(224) and can promote cell survival in response to various detrimental stimuli (56). Several 
studies reported that strategies to counteract oxidative stress hold promise for developing 
treatments to delay retinal degeneration (74), especially by preserving cones PRs (67, 73). In 
this regard, beneficial approaches for delaying cones demise should not aim to completely 




The light-induced damage in 661W cone-like cells is an appropriate model of PRs degeneration 
involving oxidative stress (225) allowed us to identify miRNAs that could be particularly 
valuable to target secondary cone degeneration in IRDs. I found that overexpression of miR-
429 prevents the damage induced in 661W cone-like cells upon prolonged exposure to intense 
light, as indicated by the results of the primary screening (HCS) of 560 miRNAs. Our results 
show that miR-429 overexpression in 661W cells also prevents the accumulation of 
intracellular ROS following the treatment with exogenous H2O2 (Figure 33). In particular, the 
ROS levels upon H2O2 exposure were significantly lower in 661W cells overexpressing miR-429 
compared to those of cells transfected with the control mimic, while being higher than those 
detected in basal conditions (Figure 34). These results suggest that miR-429 can act as a fine 
modulator of ROS levels in 661W cells, preventing their excessive accumulation, while 
preserving a minimal increase as adaptive response to the stress stimulus. It is therefore 
plausible that a fine-tuning of ROS levels could contribute to the protective effect exerted by 
miR-429 against photo-stress in 661W.  
Interestingly, studies conducted both in mice retinas (218) as well as in endhotelial (219) and 
osteoblastic cells (226, 227), indicate that the activation of the AMPK pathway is essential in 
maintaining the intracellular redox status, with one report pointing out also a role of miR-429 
(221). In the study by Guo et al., miR-429 was shown to protect osteoblastic cells from the 
damage associated with dexamethasone treatment and to attenuate the related production 
of ROS levels via the activation of AMPK (221). More interestingly, a recent study reported that 
the activation of the AMPK pathway prevents photoreceptor degeneration in different models 
of retinal degeneration, such as RP and light damage (218). In the mouse model of light-
induced damage the protection was associated with an increased mitochondrial DNA copy 
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number, increased levels of ATP, and a reduction in oxidative stress and oxidative DNA 
damage. 
Taken together, our experiments in the 661W cells are in accordance with the above-
mentioned evidence and indicate that miR-429 is able to prevent the light-induced damage in 
661W cells by activating the AMPK pro-survival pathway. To assess the extent to which the 
modulation of cellular ROS levels participates to such effect and to identify the molecular 
mediators involved, experiments measuring ROS levels in 661W cells overexpressing miR-429 
and exposed to light will be necessary. This notwithstanding, our results represent an 
encouraging premise to investigate whether the miR-429 retinal delivery can prevent or delay 
the cone degeneration also in preclinical in vivo model of RP regardless of the causative 
mutation that primarily affects rods. This kind of studies are particularly relevant to address 
the need for therapies that counteract the most severe visual impairment, that deriving from 
cone demise. 
As fine modulators acting on multiple functionally correlated pathways, miRNAs are attractive 
therapeutic targets and tools for human conditions. miRNA-based therapeutics are in the 
clinical phase of development for various diseases, e.g. liver cancer, heart failure and 
mesothelioma (228). My thesis work underscores the potential of miRNAs as molecular tools 
for gene-independent protective approaches in IRDs, expanding our knowledge on their 
mechanisms of action in preclinical models of retinal degeneration and paving the way to 
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